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Abstract 
Under appropriate conditions, certain peptides and proteins, both intrinsically disordered and 
misfolded from their native state, can self-associate to form long proteinaceous fibrils known as 
amyloids. This transition forms the molecular basis of several pathologies, through both losses of 
native functions and cytotoxic effects. Calcitonin (CT) is a 32 amino acid therapeutic hormone 
peptide that can be considered a molecular paradigm for the central events associated with amyloid 
misfolding. CT’s biological activity is limited by its aggregation along the canonical amyloid 
aggregation pathway. A better understanding of the misfolding process would not only provide a 
structural basis to improve CT’s long-term stability and activity as a therapeutic, but also provide 
valuable insights into the pathological aggregation of other amyloids. As such, the aggregation of 
human CT (hCT) has been studied in this dissertation using a range of biophysical techniques, 
with a particular focus on native modulators of kinetic behavior. 
A direct relationship between human calcitonin (hCT) concentration and aggregation lag time was 
observed for the first time, contrary to the conventional understanding of amyloid aggregation. 
This kinetic trend was found to persist over a range of aggregation conditions, as confirmed by 
Thioflavin-T kinetics assays, CD spectroscopy, and transmission EM. On the basis of kinetics 
modeling and experimental results, a mechanism whereby structural conversion of hCT monomers 
is needed before incorporation into the fibril was proposed. Comparative studies of hCT and the 
canonically aggregating salmon CT (sCT) using experimental and computational techniques 
suggested that -helical monomers represent a growth-competent species, whereas unstructured 
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random coil monomers represent a growth-incompetent species. The kinetic mechanism proposed 
represents a novel mechanism in amyloid aggregation, and synthesizes several previously 
disparate amyloid behaviors. 
The determinants of hCT lag time were further investigated in a membrane environment, providing 
the first systematic study of the effect of membranes on CT aggregation. The direct relationship 
between peptide concentration and lag phase was found to persist in the presence of large 
unilamellar vesicles (LUVs), and was shown to be dependent on membrane composition. 
Specifically, lipid compositions encouraging stronger surface interactions increased the 
concentration dependent differences in lag time. CD experiments suggested adsorption and 
sequestration of growth-competent helical monomers to play a role in this behavior. An apparent 
reformatting of mature hCT fibrils was also observed, in a process which appears dependent on 
not only lipid composition but also the peptide to lipid ratio. The ability of LUVs to remodel fibers 
grown in solution suggests that interactions between mature fibrils and lipid bilayers are causative 
in the behavior, rather than membrane-peptide interactions during fiber growth.  
The results of this thesis, particularly as they relate to monomer growth competence, represent 
significant contributions to the amyloid field and CT therapy. The novel kinetic mechanism 
proposed reveals that intramolecular interactions in disordered monomers, while often transient 
and weak compared to intermolecular interactions, can play crucial roles in mediating amyloid 
aggregation. Additionally, the elucidated effects of monomer structure and lipid interactions on 
hCT aggregation kinetics present possible means by which aggregation kinetics can be modulating 
while maintaining peptide sequence and thus therapeutic efficacy, a key goal in hCT therapies. 
Such results present a richer picture of hCT aggregation than had previously been available, and 
potentially provide novel insights as to more general mechanisms of amyloid aggregation.  
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Chapter 1 
Structural Biology of Calcitonin: from aqueous therapeutic 
properties to amyloid aggregation 
This chapter was adapted from the following publication 
Kamgar-Parsi, K., Tolchard, J., Habenstein, B., Loquet, A., Naito, A., and Ramamoorthy, A. (2016) 
Structural Biology of Calcitonin: From Aqueous Therapeutic Properties to Amyloid Aggregation. 
Isr. J. Chem. 57, 634–650 
 
1.1. Introduction to Amyloid Aggregation of Calcitonin 
The peptide hormone Calcitonin (CT) was first discovered in 1962 by Copp and 
colleagues.(1) By monitoring serum calcium levels in fasted and anesthetized dogs, it was found 
that in concert with the previously identified parathyroid hormone (PTH), an additional 
hypocalcemic factor named calcitonin was involved in the maintenance of blood calcium levels. 
These findings were reaffirmed a year later by Kumar et al.(2) Despite initial experimentalists 
ascribing a parathyroidal origin for CT, it was soon determined to be a thyroid hormone.(3) The 
32 amino acid sequence of human calcitonin (hCT) was first determined in 1968, and in the 
following years several other CT variants were discovered and sequenced, including the oft-
studied bovine, porcine, and salmon CTs.(4–7) All sequenced CTs are 32 residues in length and 
have an intramolecular disulfide bridge (Cys1-Cys7), but sequence homology varies significantly 
from species to species, with hCT differing from other CTs by as few as 2 residues (murine CT) 
or as many as 19 residues (ovine CT).(8, 9) CTs retain significant homology in the N-terminal 
residues, with the N-terminal disulfide bond in particular being conserved across all known 
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calcitonin sequences; a feature commonly thought to reduce amyloidogenic aggregation.(10) A 
comparative alignment of several commonly studied calcitonin peptide sequences is shown in 
Figure 1.1. 
 Despite the sequence diversity among CT variants, all CTs have been shown to aggregate 
into amyloid fibrils when concentrated in aqueous conditions.(11–14) The term “amyloid” 
references a specific type of supramolecular protein/peptide fibrillar architecture in which 
monomeric subunits are stacked along the fibril axis through intermolecular hydrogen bonds and 
electrostatic interactions between -strands.(15, 16) Such an amyloid fold was structurally 
characterized for aggregated calcitonin peptides by the presence of -rich conformation in hCT 
and the typical cross- structure in salmon CT by X-ray diffraction.(11, 17) This type of 
aggregation behavior and secondary structure change is observed in numerous proteins and 
peptides, and similar conformational diseases have been attributed to a wide variety of 
pathologies.(18) A significant number of human amyloid peptides have been found to play a role 
Figure 1.1. Amino-acid sequence alignment of the commonly studied human, bovine, porcine, salmon, and eel 
calcitonin. All sequences contain a disulfide bridge between residues 1 and 7, with 8 residues being conserved in all 
species (*), primarily at the N-terminus. C-terminal amino-acid sequences vary significantly between different 
homologues. Evidence for the evolutionary divergence of different CT sequences can be seen in the relative 
conservation of CT between more recently diverged species. Eel and salmon CT (eCT and sCT) differ at only 3 
locations (orange boxes), with bovine and porcine CT (bCT and pCT) also differing at 3 (blue boxes), whereas 
mammalian and fish CTs maintain less than 50% sequence homology. Colors describe residues of similar chemistry, 
asterisks denote fully conserved residues, and periods and colons indicate weak and strong conservation of amino-
acid chemistry, respectively. 
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in conferring pathological conditions to propagate diseases, including the extensively studied 
amyloid-, human islet amyloid polypeptide (hIAPP), and -synuclein peptides, which are 
implicated in Alzheimer’s disease, Type 2 Diabetes Mellitus, and Parkinson’s disease 
respectively.(19–21) Importantly, amyloids have been revealed to possess infectious properties as 
has been demonstrated for the prion protein.(22) Aggregation products and/or intermediates of 
these peptides/proteins have been shown to be toxic to various cell types or to drastically perturb 
their cellular functions.(19–21) 
The aggregation process of these peptides is thought to be highly conserved despite 
differences in primary sequences.(23, 24) For a detailed background and more details on the topic 
of amyloid aggregation, readers are referred to recent review articles in the literature.(16, 25–31) 
Briefly, unstructured monomers fold and combine to form small, intermediate aggregates 
(oligomers) during a period called the lag phase. Oligomers then gradually progress to generate 
larger protofibrillar species. Upon the formation of a critical nucleating species, amyloids can self-
template and undergo rapid fiber growth occurring during the elongation phase. These fibers can 
subsequently nucleate new protofibrils through numerous secondary nucleation pathways.(31, 32) 
Eventually, an equilibrium is reached where maximal fiber content is achieved, known as the 
plateau phase. This description of amyloid aggregation is oversimplified, however; in reality, a 
complex amalgamation of off-pathway aggregates, species metastability, and heterogeneity serve 
to obfuscate the determination of the driving factors and intermediate species in the fibrillation 
and toxicity of amyloidogenic sequences (Fig. 1.2.). Additionally, aggregation is sensitive to a 
range of environmental factors including buffer composition, salt, pH, lipids, and metals, 
highlighting the difficulties inherent in generating an all-inclusive model of amyloid 
aggregation.(16, 20) Although amyloids were originally a species of interest in disease due to their 
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propensity to form readily identified plaques, recent evidence has shifted focus away from mature 
aggregates and towards early oligomers as the putative pathological species in amyloid related 
diseases.(16, 20, 21, 33) Significant efforts are ongoing to elucidate the mechanism(s) of toxicity 
and identity the toxic species in amyloid-related diseases. 
 The amyloidogenic aggregation of CT specifically presents multiple practical challenges, 
both in normal bodily function and in therapeutic applications. While multiple variants of CT are 
known to be toxic and form membrane-permeabilizing oligomers in vitro, the roles that such 
behaviors play in vivo, if any, are not as well established as in other amyloids.(12, 34–37) To date, 
such behaviors have not been shown to have any significant roles in disease pathologies, though 
membrane interactions do hold relevance for both biological function and drug delivery. Studies 
of CT have revealed that it has skeletoprotective properties mediated through interactions with the 
Figure 1.2. Canonical amyloid aggregation pathway. The illustration presents a simplified overview of the process. 
Initially unstructured monomers aggregate into low molecular weight oligomers, which further aggregate into larger 
soluble oligomers during the lag phase. Upon formation of a critical nucleus/protofibrillar species, with a first time-
determining rate constant, k1, aggregation is self-templated and fibril elongation progresses rapidly through the addition 
of monomers or small oligomers in the elongation phase, with a second time-determining rate constant, k2. Eventually, 
fiber formation rates equilibrate, with breakage rates and fiber content remaining constant; this is known as the plateau 
phase. Typically, a majority of initial monomers are sequestered in fibrils, but small aggregates persist even after 
fibrillation is complete. This picture is complicated by the number of off-pathway intermediates, which provide 
alternative pathways to fibrils (A, C) and amorphous nonfibrillating aggregates (B). Secondary structural shifts in the 
monomer to -sheet morphology (A) and the formation of -helical peptide micelles (C) as critical species have also 
been proposed as steps in the amyloid cascade. 
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calcitonin receptor (CTR) expressing osteoclasts, leading to its use as an osteoporosis therapeutic 
agent.(8, 38) Aggregation, however, sequesters and remodels the monomeric subunits of CT and 
decreases their free concentration, consequently preventing the activation of CTRs.(39, 40) Efforts 
to combat this limited bioavailability have led to the replacement of hCT as a therapeutic agent 
with the slower aggregating salmon CT (sCT). However, not only does sCT therapy cause immune 
response correlated complications, but hCT has also been found to be more potent than sCT under 
conditions where aggregation was controlled.(40–42) Such considerations highlight why there is 
significant interest in manipulating the aggregation and structural remodeling of both hCT and 
sCT for therapeutic purposes. This introduction will examine the role of CT in normal bodily 
function, its use as a therapeutic agent, and focus on how structural considerations of the 
aggregation pathway relate to CT biology and therapy. 
1.2. Calcitonin production and expression 
The first evidence of the existence of a hypocalcemic hormone was provided in 1962 by 
Copp et al.(1) Using perfusion studies, it was found that decreases in serum calcium levels 
occurred too rapidly to be caused solely by changes in the expression of the previously known 
hypercalcemic PTH. This behavior was independently reproduced within the next year, and 
parathyroidectomy experiments initially suggested a parathyroidal origin for CT.(2) Further 
experiments revealed the true source of CT (then called thyrocalcitonin to distinguish it from the 
thought to be separate calcitonin) to be the thyroid.(3) Immunofluorescence experiments later 
determined CT to be produced solely and specifically in thyroid C-cells.(43) 
The synthesis of CT is explained in detail in other reviews.(8, 44) Briefly, CT is coded for 
by the CALC I gene. Splicing of the gene transcript at exon 4 yields CT in thyroid C-cells, with 
alternative splicing producing calcitonin gene-related peptide (CGRP), a potent vasodilator, in 
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neural cells (Fig. 1.3.). Both CT and CGRP are part of the calcitonin family, along with the 
structurally similar peptides hIAPP and adrenomedullin (AM), although unlike CGRP, hIAPP and 
AM are not alternative splice products.(45) The 32 residue mature CT, with a disulfide linker 
between residues 1 and 7, is subsequently released from thyroid C-cells following cleavage from 
a larger precursor protein.(8, 44)  
1.3. Physiological roles of Calcitonin 
 In the decades following CT’s discovery, research has revealed it to have additional 
physiological roles. Most prominent among these is its role in skeletal protection, with 
hypercalcemia prevention and gastrointestinal interactions being secondary roles. However, some 
studies have shown minimal metabolic deviations upon removal of CT, leading to speculations 
Figure 1.3. Illustration of the synthesis of calcitonin from the CALC I gene. Alternative splicing in thyroid (calcitonin) 
versus neuronal cells (CGRP) determines the hormone produced. Calcitonin is initially translated as a 17.4 kDa 
precursor protein, and then sequentially post translationally cleaved (via pre procalcitonin and procalcitonin) to form 
the 32 residue mature peptide hormone. Figure adapted from (46). 
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regarding the significance of CT’s physiological role.(47) Here we discuss the roles of CT in 
skeletal protection and hypercalcemia prevention in the body, and consider the evidence for a role 
in gastrointestinal function.  
1.3.1. Skeletal protection 
CT’s most prominent physiological role is its interaction with the skeleton to moderate 
calcium homeostasis between blood and bone. CT serves to maintain bone mass primarily by 
inhibiting osteoclasts, a bone-associated cell type responsible for bone resorption.(48–50) CT’s 
interactions with osteoclasts are mediated by the CTR, a G protein-coupled receptor widely 
expressed on osteoclast membranes.(51) Upon activation by CT, CTR causes a prompt loss in 
osteoclast ruffled border, a decreased ability of osteoclasts to acidify the bone-cell interstitial 
space, and decreased cellular motility.(52–54) All of these effects inhibit osteoclast activity and 
lead to decreased bone resorption and increased skeletal mass. The related amyloidogenic peptides 
CGRP and hIAPP have demonstrated an ability to activate CTR mediated inhibitory pathways in 
osteoclasts, although their interaction and subsequent inhibition is far weaker than the native 
substrate CT.(8) The relative affinity of the CTR for different members of the calcitonin family is 
mediated by receptor activity modifying proteins (RAMPs), and as such, elucidating the behavior 
of RAMPs is the subject of significant scientific effort.(20, 55, 56)  
In addition to interactions with the CTR, CT has other direct effects on osteoclast function. 
CT can alter the phosphorylation state of the focal adhesion proteins paxillin, FAK, and Pyk2.(57) 
A CT dependent disruption of the actin-ring structure associated with the sealing zone of 
osteoclasts has also been observed.(57, 58) Loss of focal adhesions leads to decreased efficiency 
in resorption and eventual decline in overall osteoclast numbers.(8) CT can also form calcium 
permeable pores in lipid bilayers, with some claiming that such ion flow could lead to osteoclast 
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detachment from the bone matrix.(36, 37, 59, 60) A role for calcium permeable CT pores in vivo 
requires further exploration, although calcium dependent alterations of osteoclast function are 
known.(61, 62) 
Interactions between CT and two other bone related cell types, osteoblasts and osteocytes, 
have also been observed, although such interactions are poorly understood. CT administration has 
the conflicting actions of both decreasing osteoblast function and enhancing osteoinduction.(63, 
64) Such behaviors lead to decreased and increased skeletal strength, respectively, confounding 
efforts to determine the function of CT’s interaction with osteoblasts. CT also protects both 
osteoblasts (no CTR expression) and osteocytes (CTR expression) from apoptosis, indicating an 
apparently CTR independent interaction with such cells.(65) In addition, osteocyte production of 
sclerostin, a protein associated with a decrease in bone growth, is induced by sCT.(66) These 
behaviors have led some to suggest that CT regulates bone turnover through both osteoclast and 
osteocyte interactions.(67)  Overall however, the role of CT in mediating osteoblast and osteocyte 
function remains unclear. 
Several experiments where thyroidectomy had no significant effects on long term bone 
mass have challenged the significance of CT’s role amongst the range of bone regulating 
hormones.(47, 68) Experiments have also surprisingly shown increased bone mass in 
CT/CGRPKO mouse models, although such results are confounded by the action of CGRP.(69) 
Additionally, complications from cortical porosity and overactive bone resorption were observed 
at 12 months of age in the CT/CGRPKO mouse models.(70, 71) The release of osteoclasts from 
the inhibitory effects of CT after prolonged exposure and the degradation of hCT in human serum 
are also well-established phenomena, suggesting the effect of hCT on bone cells is short-lived.(72, 
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73) It is thus likely that CT’s primary contribution to bone physiology is in short-term bone 
remodeling, or under conditions of significant calcium stress.(67, 74)  
In particular, CT is believed to play a significant role in calcium homeostasis during 
pregnancy and lactation, when maternal bone mass is under pressure from the calcium demands 
of the fetus or infant. CT stimulates the production of 1,25-dihydroxyvitamin D3 (1,25D, the active 
form of vitamin D), with elevated CT and 1,25D levels being associated with pregnancy and 
lactation, an apparently contradictory relation given the role of 1,25D in promoting resorption.(75–
79) However, CT has also shown the ability to increase intestinal absorption of calcium, and thus 
it appears as if CT could serve the dual roles of increasing dietary calcium uptake, and promoting 
calcium transfer from bone to serum (through 1,25D) during lactation and pregnancy.(78) This 
behavior would both protect the maternal skeleton and ensure sufficient calcium delivery to the 
fetus or infant. In a CT Null mouse model, the bone mineral loss during lactation and the time for 
bone mass to return to normal were both increased by the lack of CT.(77) Treatment with sCT 
rescued mineral loss and time to return to baseline.(77) As such, a heightened physiological role 
for CT during pregnancy and lactation when the mother is under elevated demand for calcium, has 
been proposed.(75, 77, 80) 
1.3.2. Hypercalcemia prevention 
The potential for CT to counteract hypercalcemia has been implied since its discovery.(1, 
2) While it exhibits no ability to directly sequester or transfer calcium, CT’s hypocalcemic function 
can be explained by its inhibition of osteoclasts; a decrease in bone resorption and transfer of 
calcium from bone to blood would decrease serum calcium levels. CT in healthy individuals under 
normal calcium load has a minimal effect, but shows an ability to decrease serum calcium under 
conditions of endogenous addition of calcium or high bone turnover.(74, 77, 81–83) As such, it 
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has been theorized that under normal conditions (no exogenous load, normal bone turnover) PTH 
governs the efflux of calcium from bone, with the influx being governed by the normal 
concentration gradient of calcium. Meanwhile, under conditions of acute hypercalcemia CT can 
decrease the efflux of calcium from the skeleton and thus reduce serum calcium levels through its 
inhibition of osteoclastic activity.(84, 85) Such a view is in keeping with the observed behavior of 
osteoclastic release from CT inhibition. It is also supported by the upregulation of CT under 
conditions of high serum calcium, and the susceptibility (and subsequent CT-based rescue) of CT 
KO mice to hypercalcemia.(67, 86) 
1.3.3. Gastrointestinal function 
Some evidence suggests that CT could also play a role in gastrointestinal function. 
Intestinal absorption of calcium is increased by CT.(78) Elcatonin, a synthetic eel calcitonin, has 
been shown to inhibit gastric and duodenal ulcers.(87) Calcitonin receptor-like receptors have been 
localized to the human GI tract, and the peptide hormone gastrin, responsible for the secretion of 
gastric acid by parietal cells, significantly upregulates CT secretion.(80, 88, 89) A similar effect 
has been found for several other gastrointestinal hormones as well.(90) The studies on GI hormone 
induced CT secretion were, however, conducted with surgically isolated thyroid glands in situ with 
direct exposure of the thyroid to GI hormones, thus it is unclear if the response has any biological 
significance. Overall, the interplay of CT and gastrointestinal function, if any, is still to be 
determined. 
1.4. Structural studies on calcitonin aggregation 
CT’s aggregation in solution is associated with non-covalent supramolecular assembly 
leading to the precipitation of the peptide. At the macroscopic level, it results in sample gelation. 
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Initial structural investigation of CT aggregation was primarily focused on these end-stage 
aggregates.(11, 91–94) Work by Arvinte and colleagues provided one of the first studies focused 
on the structure and kinetics of hCT fibrillation.(11) Arvinte found higher peptide concentrations 
correlate with decreased lag time, a behavior that has been observed for sCT, hCT, and other 
amyloids, both experimentally and in simulations.(93, 95–97) hCT also showed a propensity to 
form well-ordered fibrillar aggregates, another common characteristic of other amyloidogenic 
sequences (Fig. 1.4.).(20, 93, 98–102) TEM images of hCT indicate that short fibrils are observed 
Figure 1.4. Transmission electron microscope images of polymorphic solution structures of human calcitonin 
aggregates formed under different conditions. A) Short straight fibrils formed 90 min after dissolving 22.5 mg ml−1 of 
hCT in 20 mM sodium phosphate buffer (100 mM NaCl, pH 7.5) at 20 °C. B) Long twisted ribbon type fibrils formed 
45 days after dissolving 22.5 mg ml−1 of hCT in aqueous acetic acid (15 mM, pH 3.3) at 20 °C. C) Spherical 
aggregates together with short fibrils formed 4 days after dissolving 40 mg ml−1 of hCT in HEPES solution (20 mM, 
pH 5.6) at 20 °C. D) Dense fibrils of hCT formed from 120 μM initial monomer concentration at 25 °C in 20 mM 
sodium phosphate buffer (100,000× magnification; unpublished results from the Ramamoorthy group). TEM images 
of 0.3 mM samples of hCT after 36 hours of incubation at pH 7.4 and 298 K: E) without; and F) with 3 molar 
equivalents of EGCG (epigallocatechin 3-gallate, a polyphenolic compound extracted from green tea). Absence of 
amyloid fibers in (F) suggests that EGCG effectively inhibits the aggregation of hCT, which has been further 
confirmed by NMR experiments; mechanistic details have been reported elsewhere by the Ramamoorthy group (105). 
TEM images A)–C) were adapted from (98), while E) and F) were adapted from (105). 
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at pH 7.5, while long twisted fibrils are observed at pH 3.3 (Fig. 1.4.B and C).(103) Interestingly, 
hCT has exhibited both -helical and -sheet structures in end stage fibers, a deviation from the 
canonical view of amyloid peptides as maintaining a stable, exclusively -sheet conformation 
content.(11) Further studies have demonstrated that while -helical motifs may exist in the final 
equilibrium mixture (and indeed recent studies have identified primarily helical amyloid fibers), 
CT fibril morphology primarily relies on -sheet conformation.(12, 36, 103–109) Figure 1.5. 
shows typical NMR fingerprints, based on solution and solid-state NMR, of hCT in various forms 
(soluble and aggregated in mature fibrils). 
Subsequent studies have yielded more detailed structural data on the amyloid fibrils of CT. 
Based on solid-state NMR spectroscopy, Naito and colleagues have revealed distinct behaviors for 
the central, N-terminal, and C-terminal regions of hCT. Early species contain a central -helix, 
with a loop structure at the N-terminus and a random coil C-terminus (Fig. 1.6., monomer).(103) 
During fibril formation, the central helix converts to a -strand, with the N-terminal loop remaining 
unchanged.(103) The formation of this central -strand also results in a shorter C-terminal in 
random coil conformation, with residues closer to the central region incorporating into the -strand 
(Fig. 1.6., fiber).(104) The observation of a central -helix to -strand conversion with a structured 
N-terminus and unstructured C-terminus has been confirmed in follow up studies by both Naito 
and others.(91, 92, 98, 108, 110–112) These secondary structural changes in hCT fibrillation 
persist in both neutral and acidic environments, but pH-dependent differences in the relative length 
and orientation of -sheet motifs in the fibril do arise.(98, 104, 112) Specifically, while fibers at 
pH 7.5 assemble in an antiparallel orientation, fibrils of hCT at low pH form a mixture of parallel 
and antiparallel -sheets. It has been suggested that the charge states of the amino acids Asp15,  
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Lys18, and His20 mediate this effect.(111) It is likely, therefore, that electrostatic interactions play 
an important role in the structure and packing of CT fibers, as has also been observed for other 
amyloid peptide assemblies.(113, 114) 
Figure 1.5. Solution and solid-state NMR spectra of hCT in various forms. A) Solution NMR spectra of hCT peptide, 
in the soluble form (in blue) and in its aggregated form (in red). Signal loss in the spectra of the aggregated form is 
due to the very slow molecular tumbling that exhibits prefibrillar and fibrillar nanoobjects. B) Solid-state NMR spectra 
of the hCT fibrils. Cross-polarization experiment (in black) probes the residues in a rigid conformation. The 13C 
CPMAS spectrum shows relatively high resolution, indicative of a well-ordered core. INEPT-based polarization 
transfer from 1H to 13C (in blue) is used to probe mobile residues (faster than the microsecond timescale of motion). 
The absence of signals in the INEPT experiment indicates that all residues within the hCT peptide sequence adapt a 
rigid conformation. C) Two-dimensional 1H/1H NOESY spectrum (the Hα-HN region) of 1mM hCT (in 2 mM sodium 
phosphate buffer, 7 % D2O, 50 mM NaCl, pH = 2.9) obtained at 900 MHz proton resonance frequency with a 300 ms 
mixing time (spectrum adapted from (105)). NOEs were used to determine the structure of the peptide as reported in 
(105). D) Proton NMR spectra of hCT at pH 7.4 recorded at 600 MHz shows the temperature-dependent spectral 
resolution; line broadening of amide-NH resonances and line narrowing of aliphatic resonances were observed as the 
sample temperature was increased from 10 to 40 °C, demonstrating the feasibility of probing the aggregation at 
atomic-level resolution by NMR spectroscopy (unpublished results from the Ramamoorthy lab). 
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Figure 1.6. NMR-derived structures of monomer, oligomer, and fibril stages of hCT. The monomer and fibril 
structural models are based on NMR experiments at pH 3.3, and the oligomer structural model is based on NMR 
experiments at pH 3.3 and 7.5. The monomer exhibits an N-terminal loop, central α-helix, and C-terminal random 
coil. During early stages of oligomerization, the helix transitions to a β-hairpin, with the N- and C-termini remaining 
unchanged. This β-structure incorporates more C-terminal residues, with further aggregation, and eventually gives 
rise to a distinctive β-sheet morphology of amyloid fibrils. At low pH, the charge states on residues 15, 18, and 20 
allow for both parallel and antiparallel β-sheet stacking. At neutral pH, residue 15 and 18 possess negative and positive 
charges, respectively; thus, fibrils show antiparallel β-stacking. The structures show one possible pathway from a 
monomeric to a fibril structure, although other intermediates along the way are likely. 
Several other experiments have been carried out to probe the effect of electrostatic 
interactions on the aggregation kinetics of CT. At neutral pH, hCT contains a negative charge at 
Asp15, and positive charges at Lys18 and the C-terminal amide.(111) At acidic pH, His20 (pKa 
~6) and Asp15 (pKa ~3.6) both become protonated, changing hCT’s charge from +1 to +3.(111) 
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Increasing peptide charge by decreasing pH has been shown to slow aggregation in CT, yet 
substitution of the Asp15 with an Asn (increasing the net charge from +1 to +2 at neutral pH) led 
to accelerated fibrillation kinetics.(105, 111) In contrast, a comparison at neutral pH between hCT 
(+1 charge) and the slower aggregating sCT (+3 charge) contradicts the behavior of the Asn-hCT 
mutant relative to the wild-type.(115) The role of electrostatic interactions in CT aggregation 
kinetics must therefore be more complicated than simple net charge considerations. It is worth 
noting that all of hCT’s charged residues occur in the central region (Fig. 1.1.), associated with 
rapid formation of -helices. Consequently, hydrophobic interactions that drive fibril formation 
likely confound efforts to elucidate the precise role of charged residues in kinetics.  
Naito’s work has also implicated oligomeric intermediates with a spherical shape as 
important in seeding fibrils.(98) Such intermediates were found to serve as nucleation sites for the 
growth and elongation of mature CT fibers, and appeared to be critical for fibril formation. While 
the structure of these fibers was similar to those previously observed, the biological relevance of 
the spherical intermediates is uncertain due to the known aggregation-inhibiting properties of the 
fibrillation environment.(98) Naito’s studies have also demonstrated the importance of aromatic 
residue - stacking interactions for maintaining fibril stability.(112) This - stacking is viewed 
as an important driving force during the self-assembly of amyloid fibrils, considering its energetic 
contribution to the inter-subunit molecular interaction network and its impact into the 
directionality of the subunit stacking.(116) In this regard, Metrangolo and co. have recently shown 
that iodination of the two phenylalanine residues of hCT can amplify the fibril formation, leading 
to a 30-fold more efficient aggregation process.(117) The aromatic stacking is thought to be a 
major contributor to the difference in aggregation kinetics between sCT and hCT, given that the 
involved central aromatics Tyr12, Phe16, and Phe19 in hCT all change to Leu in sCT (Figure 1). 
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Such alterations would eliminate any stabilizing - interactions, thus decreasing the stability of 
critical aggregation species and slowing fibrillation. Indeed a recent crystal structure of hCT 
showed these -interactions to be key in stabilizing the core of hCT amyloid fibrils, and thus 
also likely key mediators of aggregation rate.(118) 
Similar to other central amyloidogenic peptide fragments, the central hCT pentapeptide 
fragment D15FNKF19 has been shown to be required for fibril formation.(108) The central residues 
of CT are believed to form the fibrillar core of the amyloid fibrils, and the pentapeptide aggregates 
into fibers with a morphology similar to that formed by the full-length peptide.(103, 106) This 
fiber formation is noteworthy due to the fairly hydrophilic nature of the pentapeptide, a challenge 
to the theory that amyloid aggregation is primarily driven by hydrophobic interactions(119) and 
rather suggests a combined mechanism of hydrophobic and hydrophilic interactions as have been 
observed for example in polyQ disease related peptides.(120) Like the full-length peptide, it is 
possible that aromatic interactions play a major role in stabilizing the fibers, although experiments 
performed with other short peptide fragments from different amyloid peptides counter this 
claim.(108, 121) Such experiments instead suggest that aromatic interactions are not necessary for 
fibrillation, but simply alter fibril structure. Regardless, experiments have clearly demonstrated 
the D15FNKF19 hCT fragment to be a key sequence in mediating fibril formation. A second 
amyloidogenic sequence of hCT towards the N-terminus, T6CMLGT11, has also been predicted, 
with an analog having been demonstrated to form amyloid fibrils, though the relevance of this 
fragment remains up for debate.(122) 
A commonly observed feature of both sCT and hCT aggregation is the formation of -
helical motifs.(11, 13, 14, 108, 123–126) Both the full-length hCT and the D15FNKF19 
pentapeptide have exhibited such structures, with -helical intermediates forming rapidly and 
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being highly stable.(103, 104, 108) The specifics of the progression from -helical intermediates 
toward the mature fibrillar structure are influenced by a number of factors including pH conditions, 
the presence of lipids, buffer composition, and the concentrations and types of salts and metal 
ions.(13, 37, 98, 101, 103, 104) Despite this variability in fibrillation, -helical intermediates have 
been observed under a range of conditions and play a significant role in the biological function of 
CT (discussed below).(11, 14, 108, 121, 127–129) It has also been reported that dimerization of 
hCT stabilizes the -helix under aqueous TFE solutions, and that this dimerization is important to 
the formation of long fibrils.(130) Within individual CT monomers there are often multiple 
secondary structural motifs present that depend on the aggregation environment and could 
influence peptide behavior, but given the ubiquity of -helical intermediates it seems generally 
accepted that they are a key species in the in vivo aggregation of CT.(103, 104, 110)   
1.4.1. Kinetic analysis of fibril formation of calcitonin 
Kinetic analyses of hCT have been performed by using solid-state 13C NMR to gain insight 
into the mechanism of fibril formation and inhibition.(98, 103, 104, 111, 112) Increased 13C 
CP/MAS NMR intensities suggest that the fibrillation can be explained by a two-step autocatalytic 
reaction mechanism, in which the first step is a homogeneous association to form a nucleus or 
intermediate and the second step is a catalytic heterogeneous fibrillation to elongate the fibril. The 
rate constants for the first step (k1) and the second step (k2) were analyzed using the following 
equation,(103) 
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where, f represents the fraction of fibril among the total population of peptide among the total 
population of peptide molecule,  = k1/k, k = ak2, and the initial peptide concentration is given by 
a. The two-step autocatalytic reaction mechanism applied to kinetic analysis of hCT using Eq. (1) 
was found to be mathematically identical to the Finke-Watzky (W-T) two-step mechanism, which 
is also used for analysis of the kinetics of fibril formation.(131) This kinetic analysis provided the 
rate constant of the first step (fibril nucleation), k1, which is responsible for the lag time of the 
fibrillation, and the rate constant of the second step (fibril elongation), which is responsible for the 
rate of fibril elongation. The rate constants for wild-type hCT and several mutants are shown in 
Table 1. Of note is the fact that k1 is consistently at least three orders of magnitude smaller than 
k2, indicating primary nucleation to be the rate limiting step in hCT aggregation, regardless of pH 
or point mutations. Additionally, the contributions of central aromatic and charged residues in 
determining the aggregation rate of hCT, particularly at neutral pH, can be seen. 
Table 1.1. pH-dependent rate constants, k1 and k2, in a two-step autocatalytic reaction       
mechanism for hCT fibril formation in solution. *F16L, F19L, Y22L-hCT 
Sample Condition k1 (s
-1) k2 (s
-1M-1) Ref. 
Wt-hCT pH 7.5 2.8 x 10-6 2.3 (103) 
Wt-hCT pH 3.3 3.3 x 10-6 2.4 x 10-3 (103) 
D15N-hCT pH 7.2 1.6 x 10-5 5.5 (111) 
D15N-hCT pH 2.9 6.2 x 10-7 5.4 x 10-3 (111) 
F16L-hCT pH 7.5 1.9 x 10-7 4.8 x 10-2 (112) 
F16L-hCT pH 2.6-3.0 1.8 x 10-6 6.2 x 10-3 (112) 
F19L-hCT pH 7.5 7.4 x 10-9 2.9 x 10-2 (112) 
F19L-hCT pH 2.6-3.0 1.3 x 10-6 1.6 x 10-2 (112) 
TL-hCT* pH 7.5 3.4 x 10-6 3.0 x 10-3 (112) 
TL-hCT* pH 2.6-3.0 5.4 x 10-6 4.8 x 10-3 (112) 
Wt-hCT (HEPES) pH 5.6 3.0 x 10-10 2.0 x 10-3 (98) 
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1.4.2. Membrane interactions 
CT-membrane interactions have been an area of interest both for the possibility of 
physiological relevance via pore formation, and for the increasing prevalence of lipid-based 
delivery options for therapies.(36, 37, 110, 132–134) As with other amyloid peptides, CT 
preferentially interacts with membranes containing anionic lipids, cholesterol, and GM1 
ganglioside.(16, 20, 24, 36, 121, 135, 136) -helical motifs in CT are often detected in membrane 
environments, and research suggests that helical intermediates are both stabilized by lipids and 
that such intermediates encourage stronger interactions with membranes, enhancing 
aggregation.(37, 137, 138) Experiments have also shown that cholesterol-rich lipid environments 
enhance -sheet content, likely the result of lipid-mediated fibril formation.(139) It seems that the 
initial species to interact with the membranes is -helical and that further aggregation in the 
membrane environment allows fibrillation to continue, eventually leading to -sheet containing 
fibrils. It would therefore appear that -helical intermediates of CT are key for aggregation in both 
solution and membrane environments. It is worth noting that several early studies of hCT and sCT 
membrane interactions used non-native, helix-inducing environments such as sodium dodecyl 
sulfate micelles, and thus caution should be used when trying to relate structures derived from 
these studies with biological behaviors of CT.(137, 140) 
Additional work by Diociaiuti and colleagues has implicated lipid rafts as having a crucial 
role in mediating the pore formation of sCT oligomers, a behavior observed in other amyloids as 
well.(136) The enrichment in lipid rafts for cholesterol and GM1 suggests that these membrane 
components could play a role in mediating interactions, although a role for lipid raft induced 
changes in membrane thickness or curvature has not been ruled out.(59) Work by Sheynis and 
Jelinek showed an interesting behavior of CT to form fibril mats on membrane surfaces without 
 20 
 
insertion, in contrast with the amyloid- whose lipid induced fibrillation is associated with a 
complete membrane rupture.(102, 135) While the possible implications of lipid raft mediated CT 
membrane interactions on pore formation are clear, the potential physiological roles for fibril mats, 
if any, remain unknown. 
1.4.3. Prefibrillar oligomers 
Compared to other amyloids, there are relatively few studies focused on prefibrillar 
aggregates of CT. However, some trends have emerged from the literature. Both annular and linear 
protofibrillar aggregates of sCT have been observed and characterized by Diociauti and colleagues, 
using both TEM and circular dichroism measurements, showing them to be primarily rich in 
random coil and -strand conformation, respectively.(12) Despite the prevalence of these larger 
species of prefibrillar aggregates, smaller (<20mer) prefibrillar oligomers are the species 
putatively responsible for membrane permeabilization, exhibiting enhanced pore-formation 
activity.(12, 59, 105, 115) As with several other amyloid peptides, pore formation by CT oligomers 
leads to calcium leakage and loss of cell homeostasis, with this behavior being modified by both 
membrane composition and membrane structure.(36, 37, 59, 60, 94) As mentioned previously, the 
biological relevance of such pore formation remains unknown. Of greater interest therapeutically 
is the fact that oligomers are thought to form critical intermediates for further aggregation of CT, 
making them a potential target for inhibition.(98)  
There is a relative lack of structural knowledge on early oligomers in CT compared to 
mature fibrils beyond the consistent formation of a central -helix. Among the few 
characterizations of prefibrillar oligomers, an NMR-based structural model for hCT at acidic pH 
obtained by Huang and colleagues indicates the formation of a -hairpin structure in the central 
 21 
 
region with an N-terminal loop and unstructured C-terminus.(105) This structure is believed to be 
stabilized by aromatic residue - interactions and is consistent with the structures of Naito and 
colleagues, representing a potential intermediate in the transition from -helix to -strand (Fig. 
1.6.). However, intermediates containing random coil, -helix, and -hairpin secondary structures 
have all been detected in CT oligomers, highlighting the heterogeneity and metastability of early 
aggregation products and the significant effect of environmental conditions.(12, 105, 110) It is 
likely that the oligomeric intermediate of Huang and colleagues represents only one of a number 
of oligomeric intermediates formed between monomers and fibers. Amongst these intermediates, 
micelle-like oligomers have been implicated in the aggregation of several other amyloid peptides, 
and unpublished results suggest such oligomers may form in the course of CT aggregation as 
well.(95, 141) Efforts to probe the role of these possible intermediates are ongoing. 
1.5. Role of calcitonin structure and aggregation in biological function and therapy 
For many of the more widely studied amyloid peptides such as amyloid- and hIAPP, the 
biological relevance of their aggregation derives directly from their influence on disease states. 
Specifically, the formation of cytotoxic oligomers and subsequent cell death is believed to be 
directly responsible for several types of dementia and other pathologies. While CT has consistently 
demonstrated the ability to form toxic species in model membrane systems and cultured cells, to 
date, the aggregation of CT in organisms has neither been shown to directly cause significant 
toxicity, nor to drive any disease pathology.(13, 34) The relevance of in vivo CT aggregation is 
instead primarily related to its roles in mitigating peptide-receptor interactions and limiting 
therapeutic efficiency through alterations of peptide structure and bioavailability.  
1.5.1. The role of CT structure on biological function 
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Research points to -helical intermediates as being key for several essential behaviors of 
CT. -helical content is directly proportional to biological activity in several CT variants.(14) In 
the therapeutically relevant sCT, the consistent formation of an -helix between residues 9 and 19 
may be a key structural determinant in mediating CT-CTR interactions.(60, 125, 126, 142) 
Interestingly, sCT mutants with excess helical content have exhibited decreased receptor binding 
affinity and hypocalcemic activity, indicating that the specific length of -helical domains 
influences biological function.(128, 143) The central -helix of hCT is significantly shorter than 
that of the sCT, and hCT has shown superior hypocalcemic activity under aggregation inhibiting 
conditions.(40, 142) A potential explanation is that the shorter -helix of hCT is superior for 
receptor activation, but either the shorter -helix or other structural elements of hCT also render 
it more prone to further aggregate. Thus it appears that there is a balancing act between monomer 
potency and stability for CT and its various isoforms. 
Mechanistically, several ideas exist as to how specific secondary structural elements 
mediate CT-receptor interactions. The N-terminal tail of CT, the most conserved section of CT 
across all species (Fig. 1), is believed to be critical for receptor activation, binding to the CTR and 
initiating its cAMP cascade.(55, 60, 123, 128, 129) This N-terminal region forms a loop structure 
in hCT as mentioned, with this structural motif persisting in a range of solution conditions. Studies 
with hCT peptide fragment 9-32 have shown helix formation upon interactions with membranes, 
but have failed to demonstrate spontaneous membrane insertion without the N-terminal residues, 
indicating the potential dual role of such residues in both receptor activation and membrane 
insertion.(123) As mentioned previously, the presence and structure of -helical motifs is also 
correlated with CT biological activity. Additionally, NMR experiments, along with the well-
established ability of -helical CT to insert into the membrane, led Rawat and Kumar to propose 
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that CT could interact with intermembrane receptor domains, although such a behavior would be 
rare amongst GPCRs.(110) Overall, it is likely that both the central -helix and N-terminal loop 
contribute to receptor activation.  
A role for the C-terminal residues of CT in receptor binding and activation is less clear, 
although recent results suggest their involvement. Johansson and colleagues recently managed to 
crystalize sCT C-terminal peptide fragments bound to the ectodomain of the CTR.(144) Using X-
ray crystallography, it was found that a type II -turn formed involving residues 28-31 of sCT, 
with this turn being complementary to a loop consisting of residues 121-128 of the CTR. Hydrogen 
bonding between sCT and CTR was also mapped, with stacking between Pro32 of sCT and Trp79 
of CTR in particular being implicated as a potential key interaction. Working with similarly 
truncated sCT and CTR models, Lee and colleagues likewise found C-terminal residues of sCT to 
form a turn and hydrogen bond with CTR residues.(55) This work also implicated the stacking of 
Pro32 of sCT and Trp79 of CTR as a potentially key mediator of CT-CTR interactions, with a 
P32Y mutation in the sCT sequence significantly weakening binding to the CTR ectodomain. 
These results suggest that C-terminal residues of CT could mediate interactions with the CTR. 
Despite these recent discoveries, prior evidence also exists that the C-terminus is not 
relevant for receptor interactions. The unstructured nature of the CT C-terminus, along with the 
lack of sequence conservation between species, suggests a minimal role in receptor activation.(60, 
91, 92) C-terminally mutated hCT peptides have shown no decrease in receptor binding or 
hypocalcemic effect, calling into question whether or not the binding exhibited by Johansson and 
Lee was sufficient for receptor activation.(128, 145) The use of truncated versions of sCT and 
CTR by Johansson and Lee along with the lack of a membrane environment and non-evaluation 
of activation also presents questions as to the biological relevance of the interactions observed.(55, 
 24 
 
144) Clearly, further experiments involving CT and CTRs are necessary to clarify the structure-
function relationship in CT mediated CTR activation. 
1.5.2. The role of CT aggregation in therapeutic applications 
Owing to its roles in mediating bone reformatting, CT has been used as a therapeutic in the 
treatment of the bone-related diseases osteoporosis and Paget’s disease to decrease the loss of bone 
mass and rate of bone reformatting, respectively.(38, 146) For details on the history of CT therapy, 
the reader is directed to a review by Henrikson et al.(147) Typically, sCT has been the most 
commonly used isoform in therapeutic applications, owing to its slower aggregation rate relative 
to hCT, which increases the amount of soluble, bioavailable monomeric peptide.(39) Despite its 
slower aggregation relative to hCT, sCT still aggregates, making it an improvement over hCT but 
still an inefficient therapeutic.(11, 112) sCT therapy is also associated with several side effects 
including anorexia and vomiting, and has been shown to cause antibody formation and immune 
response.(41, 42, 148, 149) Such reactions further decrease the efficacy of sCT treatments.(150) 
hCT is not associated with an immune response, and therefore modifications to the hCT peptide 
to increase its bioavailability are an attractive alternative to current sCT therapies.(151)  
A promising target for improving hCT bioavailability is the central aromatic residues 
Tyr12, Phe16, and Phe19. Mutation studies replacing these central aromatic residues in hCT with 
Leu (thus increasing homology with sCT) led to a decrease in aggregation rate by 2-3 orders of 
magnitude.(112) The more conservative F19Y mutation had no effect on aggregation kinetics, 
indicating that the effect of the central aromatics is general and not specific to any one amino 
acid.(112) These findings were supported by MD simulations.(112) Crucially, such mutants of 
hCT maintain their biological function, likely through stabilization of helical motifs, with both 
hypocalcemic potency and duration being enhanced over wt-hCT in rat models.(152, 153) Given 
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their significant homology to wt-hCT, it is also unlikely that such mutants would elicit immune 
response. Additionally, polyphenols, a popular class of small molecule inhibitors of amyloid 
aggregation, have proven effective in modulating the aggregation of CT.(105, 154) It is believed 
that such inhibitors operate through interference with - interactions, validating this region as a 
potential site for pharmaceutical optimization and further strengthening arguments for a strong 
role for aromatic residues in CT aggregation and remodeling.(105) 
Other modifications to hCT could also be made to decrease its aggregation propensity. The 
oxidation state of methionine at residue 8 in hCT has been shown to alter its aggregation rate in a 
pH-independent manner.(155) The absence of methionine in sCT suggests that a mutation at 
residue 8 of hCT could present another avenue for kinetics modification. Investigation by Fowler 
and colleagues found that five amino acid substitutions (T11R, N17R, N24R, I27T, V29S) in hCT 
could slow its aggregation to the rate of sCT, mainly through increasing -helix stability and 
decreasing peptide hydrophobicity.(128) Additionally, more of this -helix promoting hCT mutant 
remained soluble once aggregation equilibrium was achieved, compared to wild-type, and the 
peptide modifications did not adversely affect receptor binding or the hypocalcemic effect. 
Another study by Andreotti and colleagues found that the mutation of five central and C-terminally 
located residues in hCT to their sCT equivalents (Y12L, N17H, A26N, I27T, A31T) both 
decreased the rate of aggregation and maintained structure and biological function.(145) This 
modified hCT also had the ability to inhibit the aggregation of wild-type hCT when the two were 
co-incubated.(145) As with the mutations to the aromatic residues of hCT, the mutants of Fowler 
and Andreotti would also be expected to decrease the immune responses endemic of sCT therapy, 
given the rarity of antibody formation against hCT.(151) The decreased immune response and 
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subsequently decreased secondary resistance would further enhance the effectiveness of CT 
therapies. Such mutated hCT variants thus present another potential alternative to sCT therapies. 
CT’s interactions with lipid vesicles are also of significant interest due to the increasing 
prevalence of lipid based delivery systems for biomolecular therapeutics.(132, 133, 156, 157) 
Significant efforts have been made to modify CTs to enhance their permeability through epithelial 
layers in order to increase their effective bioavailability. It appears that -helical intermediates 
would be beneficial to that end due to their enhanced membrane insertion abilities. The formation 
of -helices by CT is enhanced by anionic lipids and cholesterol within the bilayer, and while such 
CT structures are believed to be key for receptor interactions, -helical intermediates in the 
presence of lipid bilayers also have been shown to drive fibril formation. A universal answer as to 
whether or not -helices are desirable during drug application thus appears unlikely, and would 
depend heavily on other factors (other peptide modifications, mode of intake, dosage, etc.). The 
choice of lipids in a lipid based delivery system, particularly the head group charge, could prove 
to be an attractive and simple means of controlling aggregation during peptide delivery. 
Despite the prevalence of helical intermediates, mature CT fibrils are found to contain 
primarily a -sheet secondary structure.(12, 36, 103–108) The progression of CT monomers to -
sheet fibrils via -helical intermediates would seem to mark such intermediates as a target species 
for fibrillation inhibition, but any modifications of CT fibrillation must be performed with receptor 
interactions in mind. As discussed, significant evidence exists showing -helical intermediates to 
be key in mediating peptide-receptor interactions. Therefore, direct inhibition of helix formation 
would likely render CT ineffective as a therapeutic. However, prevention of a further progression 
to -strand morphologies and fiber formation would leave biological activity intact. The 
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stabilization of helical intermediates has already been demonstrated in other systems to prevent 
fibrillation in vivo and enhance CT pore formation, indicating an increased bioavailability.(94, 
153, 158–160) Furthermore, decreased fibrillation and improved bioavailability and function are 
observed in -helix promoting hCT mutants, and residue specific data exists on the effect that 
modifying helix length and location has on peptide function.(128, 142, 143) Therefore, stabilizing 
the formation of -helical intermediates of CT appears to be one of the simplest and least invasive 
methods by which to enhance bioavailability and efficacy of CT as a therapeutic. 
1.6. Current calcitonin therapy 
The availability of other osteoporosis drugs such as bisphosphonates has led to CT therapy 
primarily being used for the short-term mediation of acute pain from osteoporosis, although 
combination treatments involving CT have shown efficacy in mediating both hypercalcemia and 
bone quality under circumstances in which other treatments were ineffective.(161–164) In 
particular, CT has seen significant use as a therapeutic for the treatment of postmenopausal 
osteoporosis.(39, 161, 165, 166) Efforts to improve CT efficacy in recent years have primarily 
focused on peptide modifications and alternative delivery methods. 
1.6.1. Peptide alterations 
In addition to preventing aggregation, therapeutic forms of CT must overcome the obstacle 
of proteolytic clearance. This clearance is especially rapid in the presence of gastrointestinal 
enzymes, with full degradation of both hCT and sCT occurring within a few hours.(167–169) 
Experiments by Doschak and colleagues also revealed a 75% loss of radiolabeled sCT within 3 
hours in major tissues in rat, with near complete loss within 24 hours.(170) Indeed, the rapid 
degradation of CT particularly in the digestive track is a major obstacle to the development of oral 
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formulations. Many prominent alternative oral delivery methods (detailed below) and peptide 
modifications are therefore focused on improving uptake and longevity. PEGylated and N-
terminally acylated sCT have both shown improved resistance and intestinal permeability, with 
PEGylated sCT also showing increased longevity and a ~3-5x improvement in hypocalcemic 
effect in rat models.(169, 171, 172)  Lipidization has also been used to improve trans-epithelial 
transport, with both reversible and non-reversible additions being explored.(173, 174) Reversible 
lipidization of sCT maintains more peptide in serum for longer, with correspondingly longer 
hypocalcemic activity.(175) Additionally, non-reversible lipidization has been shown to alter 
peptide secondary structure, which would likely inhibit receptor activation.(173)  As such, 
reversible lipidizations of sCT appear to be the more promising of the two for peptide modification.  
1.6.2. Alternative delivery methods 
Alternatives to injected and nasal spray sCT (the current preferred methods of 
administration) are being explored. The majority of these efforts focus on oral administration 
through novel delivery vessels. An oral mucoadhesive polymer delivery system developed by 
Gupta and colleagues demonstrated significant load delivery in rat intestine, and a 50-fold 
improvement in bioavailability versus direct intestinal injection.(176) Biodegradable 
nanoparticles, coated liposomes, and lipid nanocapsules have all also been shown to produce 
improved sCT delivery, both in cultured cells and through oral delivery in vivo.(132, 133, 156, 
157, 177) Despite these advances, phase III clinical trials of oral delivery methods have failed to 
demonstrate statistically significant increases in bone mineral density over nasal applications, and 
thus the development of oral delivery methods for sCT remains in progress.(165, 166, 178). The 
efficacy of all sCT treatment methods, including oral delivery, is likely still limited by sCT’s 
aggregation and limited bioavailability upon absorption. 
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1.6.3. CT Therapy and medullary thyroid carcinoma 
A commonly mentioned concern regarding the use of CT in osteoporosis therapy is the 
association between CT fibrils with medullary thyroid carcinoma (MTC) tumor cells.(179–181) It 
has been strongly suggested that CT fibrillation is a driver of tumor formation and progression.(34, 
119, 139, 154) Several problems exist with this interpretation, however. MTC is a cancer of the 
CT-expressing C-cells, thus one would expect unmitigated cell proliferation to result in excessive 
local production of CT and subsequent fibril formation. To our knowledge, as of this writing there 
is no evidence in the literature showing CT, fibrillar or otherwise, to cause MTC, with this idea 
being further challenged by the existence of CT-negative MTC tumors.(182, 183) CT’s use as a 
biomarker for MTC also suggests it to be an effect, rather than a cause, of MTC since elevated CT 
serum levels occur after tumor formation.(184, 185) Additionally, elevated CT levels do not 
necessarily correspond to the presence of MTC.(186, 187) The strongest case for an active role in 
MTC for CT is an analysis by the Food and Drug Administration and European Medicines Agency 
finding CT therapy to correlate with cancer risk.(188) However, this correlation was weak (<1% 
increase), involved clinical trials much longer than current typical dosing regimens for short-term 
use, and showed no specificity to MTC versus other carcinomas.(188) Overall, the fibrillation of 
CT seems like a consequence, rather than a driver, of MTC. 
1.7. Dissertation Objectives 
While significant advances have been made, there are still gaps in our understanding of 
hCT as it pertains to the amyloid formation process. Given the role of CTs as a therapeutic, 
significant effort has been put into structural characterizations and modifications to improve 
bioavailability. However, given the current dominance of sCT in the therapeutic market, studies 
aiming to elucidate the molecular underpinnings behind hCT aggregation have been rare, despite 
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the promise that modified hCT holds as a therapeutic. There is thus a need to elucidate the role of 
the therapeutically relevant hCT monomer structure in aggregation kinetics in order to improve 
CT therapeutics. Additionally, for the amyloid field as a whole there is a need to determine early 
drivers of the aggregation process in order to mediate or prevent aggregation before the formation 
of toxic oligomer species. In this dissertation, I first study an abnormal kinetic aggregation 
behavior of wild-type hCT in solution (Chapter 2). The observation of a direct relationship between 
peptide concentration and lag time, contrary to the typical trend in amyloids, was explained by 
self-inhibition of hCT by growth-incompetent monomers. A kinetic model for a novel mechanism 
of amyloid aggregation was devised, synthesizing several disparate previously observed/predicted 
phenomenon in amyloid aggregation.(189–191) Given the predicted importance of helical 
structural motifs in determining growth-competence, along with the aforementioned importance 
of hCT membrane interactions, I next characterized the effect of model membranes of varied 
phospholipid composition on hCT aggregation kinetics (Chapter 3). The kinetic trend from 
Chapter 2 was found to persist, and in addition several previously unreported behaviors of hCT in 
a membrane environment were elucidated. This study represents the first systematic study of the 
effect of phospholipid bilayers on hCT aggregation, and helps to both elucidate more general 
amyloid-membrane interactions as well as potentially informing future therapeutic efforts based 
on lipid delivery systems which are growing in prevalence and popularity.(132–134, 156, 157, 
192, 193) 
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Chapter 2 
Growth-incompetent monomers of human calcitonin lead to a non-
canonical direct relationship between peptide concentration and lag 
time 
This chapter was adapted from the following publication 
Kamgar-Parsi, K., Hong, L., Naito, A., Brooks, C. L., and Ramamoorthy, A. (2017) Growth-
incompetent monomers of human calcitonin lead to a noncanonical direct relationship between 
peptide concentration and aggregation lag time. J. Biol. Chem. 292, 14963–14976 
 
2.1. Introduction 
 Calcitonin (CT) is a 32 amino acid peptide hormone produced in thyroidal c-cells.(1) 
Originally discovered due to its hypocalcemic effects, further studies showed CT’s main function 
to be skeletoprotective.(1) CT inhibits bone resorption and maintains bone mass through G protein-
coupled receptor-mediated interactions with osteoclasts, and it has therefore been used as a 
therapeutic for the bone diseases osteoporosis and Paget’s disease.(1–4) However, CT-based 
therapies have been limited by the intrinsic tendency of CT to aggregate in solution as both the 
structural reformatting and sequestration of CT during its aggregation decrease bioavailability and 
efficacy.(5, 6) 
 The characteristics of CT’s aggregation mark it as a member of the amyloid family. These 
peptides and proteins are characterized by their propensity to form amyloid fibrils, in which 
monomeric subunits adopt -strand structures and stack along the fibril axis through inter-
molecular hydrogen bonding and electrostatic interactions.(7) The structure of these fibrils and the 
general process by which they form from their respective monomeric subunits is thought to be 
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relatively conserved across different primary sequences.(7, 8) Briefly, during the initial phase of 
aggregation known as the lag phase, peptide monomers self-associate to form small, soluble 
aggregates (oligomers), with continued aggregation leading to the production of protofibrils. Such 
protofibrils then seed rapid elongation through monomer addition, leading to the formation of 
mature amyloid fibrils. Crucially, the fibrillation of amyloidogenic peptides has been shown to 
play a role in a number of disease pathologies. At least 60 such peptides have been identified in 
humans, with over half having been implicated in diseases including Alzheimer’s, Parkinson’s, 
and Type 2 Diabetes Mellitus.(9–13) Despite extensive investigations, significant confusion 
remains as to the details of aggregation and the specific roles that such peptide aggregates play in 
disease pathology. The heterogeneous and metastable nature of the prefibrillar aggregates, as well 
as the large effects that subtle shifts in environmental factors have on aggregation, have combined 
to obfuscate the identification of critical aggregation intermediates or specific toxic species. A 
detailed elucidation of amyloid aggregation would both aid in disease understanding and provide 
guidance in efforts to inhibit aggregation and toxicity. 
 For CT in particular there is a need to slow aggregation to improve therapeutic efficacy. 
To this end, the rapidly aggregating human calcitonin (hCT) has been replaced by the slower 
aggregating salmon calcitonin (sCT) as the current standard in calcitonin-based osteoporosis 
therapy.(2, 14)  Despite improvements over hCT, sCT-based therapies are associated with side 
effects and immune responses that interfere with therapeutic efficacy.(4, 15, 16) Additionally, hCT 
maintains improved therapeutic efficacy compared to sCT when aggregation is controlled, and is 
free of the side effects and immune responses associated with sCT.(5, 17) Significant interest 
therefore exists in slowing the aggregation of hCT to improve its utility as a therapeutic agent.
 Here a direct relationship between peptide concentration and lag time in the aggregation of 
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hCT is shown for the first time. Such a trend goes against the conventional wisdom of the amyloid 
field, where increasing concentrations lead to faster aggregation.(18–21) In several other amyloids, 
including the closely related human islet amyloid polypeptide (hIAPP), “micelle-like” oligomers 
formed above a critical micelle concentration (CMC) have emerged as potential key kinetics-
modulating intermediates, however such intermediates in hCT were found to be kinetically 
inactive.(19, 20, 22–25) Instead, these results point to the need for monomer structural conversion 
as responsible for the trend. The concentration dependent and structural differences in these 
species were investigated and a novel kinetic model for amyloid formation by hCT was proposed. 
Further elucidation of this aggregation pathway could identify key intermediates and inform future 
efforts in kinetics modification in the therapeutic applications of CT. 
2.2. Results 
2.2.1. hCT presents an atypical direct relationship between initial monomer concentration 
and lag time 
 Thioflavin-T (ThT) assays have become the standard for kinetic monitoring of amyloid 
fibril growth due to the quantum yield increase in ThT upon binding to -sheet rich structures.(26–
30) ThT assays were used in order to probe the concentration dependence of hCT aggregation rate. 
ThT kinetic curves were measured for a range of initial monomer concentrations (Fig. 2.1.A). The 
ThT traces of hCT show the typical sigmoidal fibril growth pattern characteristic of amyloids, 
however the direct relationship between peptide concentration and lag time (time duration of the 
lag phase) is contrary to the expected behavior (Fig. 2.1. B). Amyloids typically present an inverse 
relationship between initial monomer concentration and lag time as reported in the literature.(18–
21) It is well established that the aggregation characteristics of amyloids depend heavily on their 
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aggregation environment, yet the atypical trend observed for hCT is found to persist through 
changes of buffer (concentration and type), salt concentration, pH, agitation, and temperature (Fig. 
2.2.).(31, 32) This consistency indicates the behavior to be characteristic of hCT, rather than a 
consequence of a specific set of environmental conditions. 
 To ensure that the ThT data was reflective of the macroscopic peptide behavior, rather than 
a report on a limited sub-population, population wide secondary structure was determined via CD 
spectroscopy. The time evolution of secondary structure was measured for 30 M and 120 M 
initial monomer concentrations (Fig. 2.1.C-D). At both concentrations, hCT initially displayed a 
primarily random coil secondary structure, typical for monomers of CT.(33–35)  Aggregation was 
accompanied by a depletion in the random coil peak, and subsequent increase in -sheet signal for 
Figure 2.1. hCT aggregation exhibits a direct relationship between initial monomer concentration and lag time. A) 
Normalized averaged ThT curves of hCT fibrillation at different initial monomer concentrations. Experiments were 
performed in duplicate at 25 ºC in 20 mM phosphate buffer, pH 7.4 with orbital shaking and 1 equivalent of ThT. 
Error bars represent standard deviation. B) Quantification of dependence of lag time on peptide concentration from 
A. Error bars represent standard deviation. Transition away from random coil to betasheet-like structure is seen for C) 
30 µM hCT and D) 120 µM hCT. Spectra represent averages of 5 scans. Inset shows compressed y-scale of 120 µM 
spectra at later time points. Representative TEM images of hCT at three distinct time points (early lag phase, late lag 
phase, and elongation phase) at high (120 µM) and low (30 µM) concentrations confirm fibril formation. Note that no 
concentration-dependent morphological differences are evident at any stage of aggregation. 
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both peptide concentrations, confirming the ThT-detected increase in -sheet to be representative 
of the overall peptide population. The -sheet signal was stable for at least 24 hours, indicating the 
hCT to have reached its mature fibrillar state. Consistent with the trend found from ThT 
fluorescence data, the 120 M hCT took approximately four times longer to undergo the transition 
to a -sheet conformation than the 30 M hCT. For both conditions, significant signal loss 
occurred due to the aggregation and gelation of the peptide, a phenomenon previously described 
Figure 2.2. hCT aggregates slower at higher concentrations under a range of conditions. ThT kinetic assays were 
performed with A) A range of sodium phosphate buffer concentrations without salt, pH 7.4 B) 20 mM sodium 
phosphate buffer with a range of salt (NaCl) concentrations, pH 7.4 C) A range of Tris buffer concentrations, pH 7.4 
D) In 20 mM sodium phosphate buffer under quiescent conditions, pH 7.4 E) 20 mM sodium bicarbonate buffer, pH 
10.0 F) 20 mM sodium phosphate buffer, pH 7.4. All experiments were performed with orbital shaking and 2 
equivalents of ThT other than D (no shaking, one equivalent of ThT). All plates were run at 25 °C with the exception 
of F), run at 37 °C. As can be seen, all conditions consistently show higher concentrations to aggregate slower. 
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for CT.(36) To ensure signal loss did not introduce artifacts into secondary structure 
determinations, end stage -sheet morphology was verified by single-point ThT fluorescence. 
 TEM images were also taken to further confirm the validity of the ThT and CD results. 
Aggregation of 30 M and 120 M hCT was tracked by ThT fluorescence, and samples were 
removed for imaging at equivalent stages of aggregation for both concentrations (Fig. A.1.). Early 
and late lag phase images show short, ThT-negative, protofibrillar aggregates of a few hundred 
nanometers in length (Fig. 2.1.E-H). The protofibrils are morphologically indistinguishable 
between early and late lag phase for both concentrations, with the exception of concentration-
dependent density differences. Final stage aggregates show long, thin amyloid aggregates forming 
fibrils (Fig. 2.1.I-J). Again, the aggregate morphology remains the same in both samples. Both 
concentrations exhibited the canonical progression of fibril formation via nucleating protofibrils 
and elongation, with no discernable concentration dependent differences in morphology at any 
stage. Combined with the ThT assays, these CD and TEM results confirm the direct relationship 
between peptide concentration and lag time to be a genuine behavior. 
2.2.2. Anomalous lag time dependence on peptide concentration is not entirely primary 
nucleus dependent 
 The observed hCT concentration dependent differences in lag time, combined with the 
conserved elongation rates, are consistent with theoretical predictions of differences in primary 
nucleation rate.(37) The lack of concentration dependent morphological differences in 
protofibrillar or fibrillar aggregates by TEM or CD supports the idea that concentration dependent 
changes in lag time involve the rate of nucleus formation, rather than the characteristics of the 
nucleus itself.(38) To probe this hypothesis, seeded ThT kinetics assays were performed.(39–41) 
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Although the addition of seeds accelerated fibril formation, an extended lag phase remained even 
in the presence of high seed concentrations (Fig. A.2.A). Additionally, in the presence of seed, the 
monomer concentration dependence of the lag phase was abolished (Fig. A.2.B). A lag time 
independent of free monomer concentration is expected for seeded ThT assays, and is consistent  
with differences in primary nucleation rate contributing to the direct relationship between lag time 
and peptide concentration. However, the persistence of an extended lag time even with 15% 
seeding by volume implies that the existence of primary nuclei is not sufficient for fibril formation 
and elongation, with such a phenomenon having been previously shown in other systems.(42)  
2.2.3. hCT oligomer behavior changes with concentration 
 The results of seeded ThT kinetics assays focused further analysis on the presence and 
interconversion of oligomeric intermediates which dominate the lag phase. In order to probe the 
kinetics of oligomerization, rather than fibril formation, the time evolution of hCT aggregate size 
was monitored using DLS experiments. Despite peptide preparations minimizing the number of 
non-monomeric species initially present, peaks representing small oligomeric species and larger 
aggregates appear rapidly after sample preparation, at both high (120 M) and low (30 M) hCT 
concentrations (Fig. 2.3.A). In order to confirm the detected species as hCT aggregates rather than 
artifacts, Epigallocatechin gallate (EGCG), a natural product known to interact with and break 
apart amyloid aggregates including oligomers of hCT, was added.(33, 43, 44) The addition of 
EGCG shifted the small oligomeric peak from 2-5 nm to less than 1 nm in radius, confirming the 
source of the peak to be small soluble aggregates (Fig. 2.3.A). The peak associated with larger, 
potentially protofibrillar aggregates was unaffected by EGCG. Previous studies have revealed the 
effect of EGCG on hCT aggregates to be mediated primarily by interactions between the aromatic 
rings of EGCG with those of Tyr12 and Phe16.(33) The ability of EGCG to remodel only low 
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molecular weight aggregates by DLS would suggest the larger aggregates to be significantly more 
stable, potentially due to the sequestration and subsequent solvent inaccessibility of the aromatic 
residues.  
Figure 2.3. Concentration-dependent differences in early aggregates of hCT. A) Representative sample of hCT DLS 
profile at early time-points with and without EGCG. Peak I represents low molecular weight soluble oligomers, while 
Peak II represents larger aggregate species. B) Time-course measurement of oligomer radius shows a consistently 
larger radius at higher concentrations, indicating a concentration dependent change in small oligomer formation. C) 
Time-course measurement of protofibril peak shows accelerated growth at higher concentrations. Note that initial 
protofibril peak size is equivalent for both concentrations, thus differences in size at later time points are indicative 
of post aggregate formation changes. All DLS profiles represent averages of 10 independent acquisitions. The time 
evolution of the oligomer peak at 30 µM hCT (D) and 120 µM hCT (E) indicates differences in oligomer reformatting. 
F) Plot of oligomer peak intensity normalized to oligomer peak intensity at t=0 versus time for both 30 µM hCT and 
120 µM hCT, determined via fixed bound integration. G) 1H NMR spectra for 120 µM hCT. Spectra show negligible 
intensity loss over the course of the experiment outside of the peak at -0.1 ppm (black arrow). 
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 In EGCG-free preparations, two clear differences in aggregate size appear. First, the 
smaller peak representing low molecular weight oligomer species shows consistently larger 
aggregates for 120 M hCT (4-5 nm radius) as opposed to 30 M (1-2 nm radius) (Fig. 2.3.B). 
Such a finding suggests that the oligomeric population is concentration dependent, favoring larger 
oligomers at higher concentrations. Second, the observed changes in the larger peak initially 
appearing at ~100 nm for both conditions indicate a significantly faster growth for samples 
containing 120 µM hCT compared to those containing 30 µM, which suggests a more rapid re-
organization of aggregates to larger species at higher concentrations (Fig. 2.3.C). DLS results do 
not exhibit any statistically significant concentration- or time-dependent differences in mass 
distribution between peaks. The majority of peptide mass (~80%) is contained in peak I as expected 
for early aggregation stages (Fig. A.4.), indicating that the relative percentage of peptide in each 
peak remains fixed over the time course measured in the experiment.  
 To further probe the concentration dependent time evolution of hCT oligomers, a time 
course 1D 1H NMR experiment was used to track the progression of oligomerization by monitoring 
the peak at -0.1 ppm. This peak appears in the NMR spectra of amyloidogenic peptides when 
aliphatic protons are shielded from solvent, as occurs when they are sequestered in oligomeric 
aggregates.(30, 33, 45) Monitoring the time evolution of this peak at high and low concentrations 
provides information on the concentration dependence of oligomerization kinetics specifically, an 
alternative to typical kinetic assays which track only fibrillation kinetics.  
 At both concentrations, an oligomer peak was found immediately, consistent with the DLS 
data. Over time, the oligomer peak intensity decreased for both peptide concentrations (Fig. 2.3.D-
E). Interestingly, the 1H NMR spectra revealed a slower loss of oligomer peak intensity at higher 
concentrations (Fig. 2.3.F). This would initially appear a trivial result, given that the ThT and CD 
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time course experiments both exhibit slower aggregation at higher concentrations, implying a 
longer period of oligomer-dominated peptide distribution and slower loss of signal intensity to 
NMR-invisible species. However, the overall spectrum signal intensity for both concentrations is 
unchanged over the course of the experiment (Fig. 2.3.G), indicating the differential rates in 
oligomer peak intensity loss to be independent of fibrillation, and instead representative of 
concentration dependent differences in oligomeric reformatting. It is important to note that given 
the NMR-invisible size of the larger, rapidly growing aggregate species detected by DLS (peak 
II), the changes in the oligomer peak detected by NMR must represent a different process, 
involving changes in either oligomer packing or prevalence. Taken together, both the DLS and the 
NMR data confirm concentration dependent differences in early oligomeric behavior, independent 
of primary nucleus formation. Specifically, higher hCT concentrations exhibit larger and longer 
lived oligomers during the lag phase than lower hCT concentrations. 
2.2.4. The effect of micelle-like oligomers on hCT aggregation 
 Given a postulated oligomeric culprit driving the abnormal hCT aggregation, a potential 
role for micelle-like oligomers was investigated. In contrast to amyloid oligomers as typically 
described, which form over a range of concentrations with varied sizes and morphologies, micelle-
like oligomers form exclusively above their critical micelle concentration (CMC). Additionally, 
such oligomers consistently result in the shielding of hydrophobic peptide regions in the 
oligomeric interior, analogously to lipid micelles. Studies have reported that several amyloid 
proteins including amyloid-, hIAPP, and PrP form such oligomers, with these oligomers 
exhibiting significant effects on aggregation kinetics.(19, 20, 22–25) The formation of micelle-
like oligomers has also been proposed, but not detected, for hCT and provides a potential 
mechanism for the concentration versus lag time trend.(32, 46) At higher concentrations an 
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elevated number of micelle-like oligomers could pull progressively larger amounts of monomers 
off-pathway, providing a sink for monomers and resulting in slower aggregation. 
 The formation of micelle-like hCT oligomers was determined by monitoring the 
fluorescence spectrum of pyrene, a well-established technique for detecting micelle formation.(19, 
47, 48) Pyrene emission spectra were collected with changing peptide concentrations, and the peak 
I/peak III intensity ratio plotted against concentration (Fig. 2.4.). This ratio undergoes a sharp 
decrease upon crossing ~80 M peptide, indicating that micelle-like hCT oligomers form above 
this CMC. The pyrene spectral shift occurs at roughly the same concentration with both increasing 
(titration) and decreasing (dilution) peptide concentrations, indicating that the formation of the 
micelle-like oligomer is reversible. This formation of a reversible micelle-like oligomer of hCT is 
Figure 2.4. Pyrene detects a micelle-like oligomer in hCT. A) Fluorescence spectra of pyrene normalized to peak I. 
The shift in peak III at different concentrations relative to peak I is indicative of micelle formation. B) Plot of pyrene 
I/III ratio over indicated hCT concentration range. Dashed lines indicate initial formation (titration) or final 
dissolution (dilution) of hCT micelle-like oligomers. I/III ratio determined from average of three scans. 
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consistent with the behavior of similar aggregates in other amyloids, and represents the first direct 
confirmation of micelle formation by hCT.(19, 20, 22)  
 Despite confirming their formation, results to this point suggest that micelle-like oligomers 
of hCT play no role in the anomalous concentration dependent aggregation trend observed. The 
relationship between lag time and peptide concentration displays no discontinuity at or above the 
CMC, as would be expected if micelle-like oligomers were involved (Fig. 2.1.B). This kinetic 
inactivity of the micelle-like oligomer of hCT is at odds with the behavior of similar aggregates in 
other amyloids, and casts doubt as to its role in previously proposed hCT aggregation pathways.  
2.2.5. Inhibition by growth-incompetent hCT monomers explains the anomalous trend in 
concentration versus lag time 
The micelle independence of the atypical concentration versus lag time trend, combined with the 
persistence of a long lag phase in the presence of seeds, necessitates another determinant of lag 
time. The existence of no apparent concentration dependent morphological differences in 
protofibrillar or mature fibril species suggests the canonical elongation and fragmentation 
mechanisms for amyloid fibril kinetics to be at work.(37) Additionally, the persistence of a 
prominent lag time in the presence of seeds would suggest that initial hCT peptides are different 
from classical monomers in that they cannot immediately be incorporated into fibrils during 
elongation. Such a difference could arise through the need for a structural conversion step in the 
monomers before they are growth-competent. As such, the inverse dependence of lag time on the 
monomer concentration can be explained by the existence of two distinct types of monomers, 
growth-competent and growth-incompetent (see Section 2.4.8. for model details). Such 
promiscuity in monomer conformation inhibits the formation of mature fibrils by both limiting the 
availability of growth-competent monomers and through the formation of slowly reversible 
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Figure 2.5. Monomer conversion allows accurate kinetic modeling of observed trend between peptide concentration 
and lag time. A) Reaction diagram for hCT fibrillation and comparison between experimental (colored squares) and 
computational (dashed lines) evolutions shows model to recapitulate experimental trend. Global fitting (dashed lines) 
was performed according to Eq. 1 with kn = 1.8x10−4 h−1 , ke = 1x105 µM−1 h−1 , kmc = 3.5x102 h−1 , kfc = 1.9 h−1 , kb+  
= 1.2x105 µM−1 h−1 , kb− = 1.4x10−7 h−1 , kf = 1x10−2 h−1 , and nc = 1. B) Comparison of dependence of lag time on 
peptide concentration between experimental and computational results. Lag time for both computational and 
experimental data is determined according to fitting with Eq. 1. C) Removal of lateral structure conversion from 
protofibril to mature fibril will cause a gradual decrease in predicted curve slopes. The best global fitting is shown 
according to Eq. 1 with kn = 2.2x10−3 h−1 , ke = 1x105 µM−1 h−1 , kmc = 98.6 h−1 , kb+ = 2.7x104 µM−1 h−1 , kb− = 
1.87x10−9 h−1 , kf = 7.3x10−2 h−1 , and nc = 1. D) Removal of the monomer inhibition step on protofibril elongation 
will cause the disappearance of the inverse relationship between lag time and peptide concentration. Curves are drawn 
based on best global fitting with kn = 4.9x10−3 h−1, ke = 1x105 µM−1 h−1, kmc = 58.3 h−1, kfc = 1.3 h−1, kf = 1.6x10−3 h−1, 
and nc = 2.3. 
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growth-incompetent aggregates (Fig. 2.5.A). Such a model accurately reproduces the experimental 
data showing a direct relationship between lag time and monomer concentration (Fig. 2.5.A-B). 
Details of model species evolution, rate constant influence, and sensitivity analysis are provided 
in Appendix A (Fig. A.4.-A.6.). 
 Comparisons between the current model and other unsuccessful models are shown in Fig. 
2.5.C-D, highlighting the necessity of key model elements. Note that the removal of the monomer 
conversion step in the current model leads to a reversion to the canonical relationship between 
peptide concentration and lag time, as has been previously shown in the literature.(37, 49) 
2.2.6. MD simulations implicate -helical structure as critical for monomer growth-
competence 
 In order to correlate this study with other kinetics studies focused on maintaining 
monomeric CT for therapeutic applications, the behavior of hCT was compared with the 
therapeutically preferred sCT (Fig. 2.6.A). As expected, sCT exhibited significantly longer lag 
times than hCT under identical conditions (Fig. 2.6.B). However, despite the significant sequence 
homology, under identical conditions sCT displays the canonical relation between lag time and 
peptide concentration for amyloids, in contrast to hCT. According to the kinetics modeling, the 
reversion of sCT to the canonical relation between peptide concentration and lag phase should be 
correlated with a difference in the initial structures in sCT as compared to hCT. Experimental 
methods to distinguish specific monomer or oligomer conformations in the interconverting and 
heterogeneous pre-fibrillar milieu have yet to be achieved in amyloid research. In order to 
circumvent these limitations, molecular dynamics (MD) simulations were utilized to probe the 
relative distributions of hCT and sCT monomers in solution. MD simulations show sCT to sample 
a more compact region of conformational space and occupy fewer structural basins (clusters) on 
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Figure 2.6. Molecular dynamics simulations implicate α-helical structure as key in determining monomer growth-
competence. A) Comparison between the sequences of hCT and sCT. Non-conserved residues shown in red. B) sCT 
and C) hCT at low pH display the typical relationship between lag phase and peptide concentration. Experiments 
performed in duplicate at 25 ºC in 20 mM phosphate buffer, pH 7.4 for sCT and 20 mM citric acid buffer, pH 3.3 for 
hCT. Curves normalized to 60 µM max fluorescence and 40 µM max fluorescence for sCT and hCT, respectively. 
Structural models representing the 4 most populated clusters and the relative percentage of monomer found in each 
cluster for D) hCT, E) sCT, F) hCT mutant, and G) low pH hCT. Models show sCT with the highest helical propensity, 
hCT the lowest, with the hCT-mutant and low pH hCT again being intermediate to hCT and sCT (sCT > hCT mutant 
= hCT (low pH) > hCT). 
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its energy landscape than hCT, with 82% of sCT conformations falling in the 4 most populated 
clusters compared to just 26.4% for hCT (Fig. 2.6.D-E, Fig. A.7.). sCT monomer conformations 
had smaller radii of gyration and a more compact distribution of end-to-end distances than hCT 
(Fig. A.7.C-D). sCT also shows several discrete overrepresented end-to-end distance values 
relative to a normal Gaussian distribution, further hinting at increased structure. Significantly, sCT 
monomers show increased numbers of helix-incorporated residues as compared to hCT, a finding 
in keeping with previous comparative studies (Fig. A.7.B).(50, 51) This increased helical structure 
in sCT versus hCT immediately after peptide solubilization was confirmed by CD measurements 
(Fig. 2.7.). The decreased conformational heterogeneity and more structured helical sCT monomer 
as compared to hCT is consistent with the kinetic model predictions of differing degrees of 
monomer heterogeneity, leading to the canonical inverse relationship between lag time and 
concentration in sCT. Specifically, the increased helical structure in the sCT monomer would 
suggest that this more structured, “sCT-like” monomer represents the growth-competent species, 
whereas the less ordered “hCT-like” species represent the growth-incompetent species, which 
requires conversion through oligomeric intermediates to gain structure and proceed to fibril 
incorporation. 
 While the precise causes for these differences between hCT and sCT remain unknown, one 
possible explanation lies in the mutation of the three central aromatic residues in hCT (Tyr12, 
Phe16, Phe19) to Leu in sCT. The associated - stacking interactions in hCT have been confirmed 
by NMR and crystallography as crucial in driving fibrillation, with mutations in these three 
residues increasing hCT lag times to be comparable with sCT.(52, 53) The ability for EGCG to 
dissociate early aggregates in hCT believed to be associated with monomer conversion suggests 
that aromatic residues play a key role in said conversion as well. As such, MD simulations were 
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performed on a hCT mutant (Y12L, F16L, F19L) to probe the role of these residues in the 
monomer conformational heterogeneity and structure. Interestingly, the mutated hCT behaved in 
a fashion intermediate to hCT and sCT: the mutant displayed decreased conformational 
heterogeneity, increased -helical content, and decreased radii of gyration and end-to-end 
distances as compared to wild-type hCT, rendering it more “sCT-like” (Fig. 2.6.F, Fig. A.7.). The 
MD simulations thus support the idea that these residues are important for not only interpeptide 
stabilizing interactions, but also as intrapeptide conformational constraints.   
 Similarly to the hCT mutant, hCT under low pH conditions (pH 3.3) was also observed in 
MD simulations to exhibit increased helical structure in the monomer and become more “sCT-
like” (Fig. 2.6.G,  Fig. A.7.).(32, 33, 46) Critically, ThT experiments with hCT at low pH actually 
show a reversion back to the canonical amyloid relationship with this increased monomer 
Figure 2.7. Circular Dichroism measurements support MD simulations on -helical propensity. CD spectra of hCT 
(pH 7.4), sCT (pH 7.4), and hCT (pH 3.3) are shown immediately after sample preparation. Curves are normalized 
to -5 mdeg at 200 nm to allow direct visualization of α-helical content relative to random coil. Spectra represent 
averages of 5 scans. As is quantified in the inset, sCT shows the strongest α-helical signal relative to random coil, 
with hCT (pH 7.4) and hCT (pH 3.3) showing lower helical content. Looking at lineshapes indicates hCT (pH 3.3) to 
have a more pronounced shoulder at 222nm as compared to hCT (pH 7.4), indicating increased helical content despite 
similarity in the 222nm/200nm ratio and showing the CD results to agree with simulations. 
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structure, similarly to sCT (Fig. 2.6.C). Further, CD experiments confirm freshly dissolved hCT 
at low pH to contain -helical structure intermediate to sCT and hCT at neutral pH, consistently 
with MD simulations (Fig. 2.7.). This data provides further evidence that more structured, “sCT-
like” monomers, specifically with -helical motifs, represent a growth-competent species that 
allows fibrillation along the canonical amyloid pathway. 
2.3. Discussion 
 A direct relationship between amyloid concentration and lag time has only been observed 
twice prior, both times in light chain amyloids.(54, 55) In these studies, a dimer-monomer 
exchange mediating the relative native state population was proposed, with higher concentrations 
favoring the non-fibrillating dimer and slower aggregation. The formation of an anti-parallel 
helical dimer has been shown to slow aggregation in sCT as well, however the experiments 
performed in this study give no evidence for such dimer formation being causative in the trend.(56) 
Indeed, if such a helix mediated dimer were the causative species, one would expect the more 
helical sCT, rather than hCT, to display the direct relationship between lag time and concentration. 
This study instead suggests that while helix formation is key in hCT aggregation, structural 
differences in free monomers, rather than an aggregate mediated sequestration, result in the 
increase in lag time with higher peptide concentration.  
 The existence of growth-competent and growth-incompetent monomers has been proposed 
previously, however several novel aspects of the current model warrant further consideration.(57) 
The reproduction of the reported trend requires the monomer conversion rate to depend inversely 
on initial peptide concentration, with a relatively slow rate constant. Such a phenomenon is 
unsurprising if one assumes monomer conversion to occur indirectly through the formation and 
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dissociation of low molecular weight oligomeric intermediates. According to the Ostwald ripening 
mechanism, the dissociation of larger particles is slower than that of smaller ones, with the time 
being roughly proportional to particle size.(58, 59) As such, one would expect the rate of 
oligomeric reformatting, and thus monomer conversion, to be inversely proportional to oligomer 
size. Not only is this differential rate of oligomer reformatting seen in the time-course NMR 
experiments, but the larger size of initial small oligomers observed at higher concentrations by 
DLS provides direct evidence for the existence of such an intermediate species. The inverse 
dependence of the kinetic term kmc on mtot incorporates these results into the kinetic model. 
 Additionally, the current model proposes the existence of off-pathway protofibrillar 
species, which persist without immediately elongating to fibrils. In particular, these off-pathway 
species could be formed by the addition of growth-incompetent monomers to growth-competent 
aggregates, essentially providing a means by which such monomers inhibit further growth and 
elongation. The detection of larger ThT-negative aggregates in the lag phase by DLS and TEM 
such as those predicted by the model during the lag phase, before mature fibril formation and 
elongation, is consistent with this model. Interestingly, the lack of a ThT-detectable -sheet signal 
from these protofibrils as well as the marked morphological differences between protofibrils and 
mature fibrils hints at possible structural conversion steps in addition to the monomer conversion. 
Such a lateral structure conversion is fully consistent with previous hCT studies and the 
requirement of a unimolecular reaction, which accounts for the concentration independence of 
elongation rate observed in the ThT traces.(60)  
 Despite the support our kinetic model enjoys from both previous and current works, it is 
important to note that the complexity of the amyloid aggregation process likely is not fully 
encapsulated in the kinetic parameters described; other rate-determining species and conversions 
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in addition to those explicitly described are likely present. Furthermore, again owing to the 
metastability and heterogeneity of aggregate species, a direct experimental isolation and 
quantification of individual rate constants is not possible. An evaluation of the ability of the model 
to predict and reproduce experimentally induced changes in aggregation kinetics, e.g. through 
alterations of aggregation environment, would be valuable in determining model validity. Thus 
while the current model does present a viable and supported explanation for the kinetic trend, 
further experiments are required.   
 Interestingly, MD simulations show both the hCT mutant and hCT at low pH to form an 
amphipathic -helix in the central region between Asp15 and Phe19, while such a helix is absent 
in the wild-type hCT. This central DFNKF region (DLNKL in the hCT mutant) forms the core of 
hCT fibrils, and has previously been shown to adopt a helical conformation in monomers, as 
determined by NMR.(46, 61, 62) The results in this study suggest that the helical structure of the 
Figure 2.8. ThT kinetics assays at pH 5.4 indicate the direct relationship to remain, implicate Asp15 in determining 
growth-competence. Assays were performed in triplicate using citric acid buffer, pH 5.4, at 25 ºC, with orbital shaking 
and 2 equivalents of ThT. The similar relationship between lag time and concentration at pH 7.4 and 5.4 indicates the 
behavior to be independent of the charge state of His20 (pKa = 6). 
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DFNKF region may be key in determining the growth competence of hCT monomers, potentially 
by driving initial monomer self-recognition events through hydrophobic interactions. Low pH 
environments and leucine residues have both previously been shown to enhance helical propensity, 
consistent with the above findings.(63, 64) In particular for hCT going from pH 7.4 to pH 3.3, the 
side chains of Asp15 and His20 both become protonated. Given the proximity of these residues to 
the central helix forming region, they present likely causes for the pH dependent change. ThT 
kinetics experiments at pH 5.4 (where His20 is protonated but Asp15 is not) reveal the maintenance 
of the direct relationship between concentration and lag time, suggesting that the charge state of 
Asp15 plays the larger role in the pH-determined growth-competence of hCT monomers(Fig. 2.8.). 
Further experiments involving the above-mentioned hCT mutant and other, more structured hCT 
monomers will be valuable in fully understanding the role of monomer structure and concentration 
in determining lag time. 
 Previous studies have reported both hCT and sCT to exhibit -helical structural motifs 
during the progression to mature -strand conformations, consistently with the predictions of this 
study.(6, 65–70) Note that the dominance of random coil structure in this study’s CD experiments, 
with smaller amounts of helical structure are not contradictory to previous studies. The predicted 
monomer structures of hCT and sCT, both here and in other studies, maintain extended 
unstructured regions, with limited numbers of helical residues. Additionally, the relatively rapid 
incorporation of converted monomers into fibrils, a mechanism consistent with previous amyloid 
research and exemplified in Figure A.4.A, would serve to preferentially sequester helical 
monomers in favor of less structured monomers.  
 In light of the fact that low pH conditions and mutated hCT have been shown to slow the 
aggregation of hCT, it is important to note that the shift to a more “sCT-like” growth-competent 
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monomer is not proposed to represent an overall acceleration of the aggregation pathway, but 
rather a loss of need for monomer reformatting, and thus a return to the canonical relation between 
peptide concentration and lag time. Despite this, a correlation does exist between the degree of 
monomer structure and lag time. A hypothesized explanation is that the more stable helices in 
“sCT-like” monomers, while encouraging initial monomer interactions and aggregation events, 
could resist conversion to -sheet structures thus delaying overall lag times. This explanation finds 
support in the reported delay of sCT aggregation by helical dimers, mediated by the helical 
propensity of the monomer and stabilizing hydrophobic leucine interactions between helices.(56, 
71) It seems likely that the observations of monomer helical stability being correlated with slower 
lag times are due to the formation of similar stable helical structures, but further studies are 
required to confirm the persistence of this behavior in the above experiments.  
 Interestingly, it appears that micelle-like oligomers play no significant role in hCT 
aggregation, in contrast to other amyloids. In addition to being kinetically inactive, the above CD, 
NMR, and TEM experiments showed no structural or morphological differences upon the 
introduction of micelle-like oligomers through increased concentration. TEM measurements do 
show punctate proteinaceous aggregates in the late lag phase above the CMC only, with such 
aggregates being absent at low concentrations (Fig. A.8.). Such aggregates may be the micelle-
like oligomers, but show no spatial association with other aggregates, further suggesting a non-
functional role. Naito and colleagues previously observed spherical aggregates of hCT to form in 
HEPES buffer.(32) Such oligomers were shown to seed fibril formation, and micelle-like 
oligomers were proposed as a preceding species to these spherical aggregates. Given the lack of 
kinetic influence or fibril association of the micelle-like oligomers detected in this study, it would 
seem that the spherical aggregates formed in HEPES buffer could form in a micelle-independent 
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fashion. The kinetic inactivity of micelle-like oligomers of hCT observed in this study is especially 
confounding given recent work highlighting the role of such oligomers in the aggregation of the 
related peptide hIAPP.(20) Both hCT and hIAPP belong to the calcitonin family, bind to the same 
receptor, contain an N-terminal disulfide bond, and possess similar numbers of residues and 
charges. The causes for this deviation in oligomer influence are unknown, and are confounded by 
the reversible formation of oligomers and the difficulty in isolating them from the pre-fibrillar 
milieu. 
 The reported relationship between concentration and lag time in hCT also holds therapeutic 
promise through the possibility for higher effective doses of hCT without the correlated hindrance 
of decreased bioavailability. Indeed such a phenomenon has broad interest for all fibrillating 
therapeutic peptides, e.g. insulin, where large local peptide concentrations and subsequent 
aggregation pre-uptake, for example within nanoparticles, pose obstacles to therapeutic efficacy 
and alternative therapeutic delivery methods.(72–77) With the increasing prevalence of therapeutic 
peptides in the pharmaceutical market, such issues are taking on progressively more importance. 
The direct relationship seen here between lag time and peptide concentration could inform future 
efforts to design appropriate peptide delivery systems, and allow the packaging of higher dosages 
of peptide without loss of efficacy. 
2.4. Materials and Methods 
2.4.1. Peptide preparation 
 Human calcitonin peptide was synthesized via Fmoc chemistry as described 
previously.(33) The disulfide bond between Cys1 and Cys7 of hCT was formed by air oxidation 
at pH 8.0-8.5 at diluted concentration and in the presence of 6 M urea to prevent fibrillation. To 
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ensure consistent monomeric starting conditions, peptide was dissolved in hexafluoroisopropanol 
(HFIP) at a concentration of 1 mg/ml. Peptide was then separated into 100 L aliquots, flash frozen 
in liquid nitrogen, and lyophilized for a period of 48 hours. After lyophilization, peptide aliquots 
were stored at -20 ºC until use. Peptide solutions were prepared by resolubilizing the lyophilized 
aliquots in 100 L of HCl pH 4 at 4 °C to a concentration of ~300 M, followed by brief sonication 
to ensure peptide dissolution. Peptide solutions were then warmed to room temperature and 
subsequently used.  
2.4.2. Thioflavin-T Kinetic Assay 
 Thioflavin-T (ThT) experiments were run on a Biotek Synergy 2 microplate reader 
(BioTek Instruments, Inc., Winooski, VT, USA) on uncoated Fisherbrand 96-well polystyrene 
plates. Peptide was added to final concentrations of 20 mM buffer and ThT at 25 ºC, and 
immediately prior to acquisition. Experiments were performed in duplicate with two equivalents 
of ThT and 100 L total volume unless otherwise indicated. Wells were bottom read with an 
excitation wavelength of 440 nm (30 nm bandwidth) and emission wavelength of 485 nm (20 nm 
bandwidth). Curves were normalized, averaged, and kinetic parameters t50 and tlag calculated via 
fitting to the equations:(26)  
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For seeded assays, seeds were generationally created to ensure uniform morphology(78) 1st 
generation seeds were created at 120 M in 20 mM phosphate buffer at 50 L volume, at 37 °C 
shaking at 1000 rpm for 24 hrs. Subsequent generations were seeded by the previous generation at 
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10% by volume, and incubated under identical conditions. 4th generation seed was seeded 
identically with 200 L final volume. 4th generation seeds were used for ThT kinetics assays 
2.4.3. Circular Dichroism 
 Circular dichroism (CD) spectra were taken on a Jasco J-1500 Circular Dichroism 
Spectrometer (JASCO, Inc., Easton, MD, USA). Spectra were recorded at 25 °C with 120 M hCT 
and 30 M hCT concentrations in 20 mM phosphate buffer pH 7.4 in a 1 mm quartz cuvette unless 
otherwise indicated. Spectra were recorded with 2 nm bandwidth, 1 nm step size, scan speed of 
100 nm/min, baseline corrected, and averaged over 5 scans. Smoothing was performed using the 
Savitzky-Golay method, with a convolution width of 15. Between reads, peptide samples were 
transferred to a microcentrifuge tube and vortexed for 2 s every 10 minutes.  
2.4.4. Transmission Electron Microscopy 
 Samples for transmission electron microscopy (TEM) were removed at 3 separate time 
points from a single well of a ThT plate and flash frozen in liquid nitrogen. Glow-discharged grads 
(Formar/Carbon 300-mesh, Electron Microscopy Sciences, Hatfield, PA, USA) were treated with 
the samples for 2 min at room temperature. Excess sample was removed with filter paper and 
washed three times with ddH20. Each grid was stained with uranyl acetate (1% w/v, ddH20, 5L, 
1 min), blotted to remove excess stain, and dried for 15 min at room temperature. TEM images 
were recorded on a JEOL 1400-plus TEM (80kV) (Microscopy and Image Analysis Laboratory, 
University of Michigan, Ann Arbor, MI, USA). 
2.4.5. Dynamic Light Scattering 
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 Dynamic light scattering (DLS) measurements were taken at 25 ºC using a DynaPro 
NanoStar Dynamic Light Scattering Spectrometer (Wyatt Technology, Santa Barbara, CA, USA). 
All reagents and buffers were syringe filtered (0.22 m pore size) prior to sample preparation. 
Initially monomeric aliquots of hCT were added to a final peptide concentration of 120 M or 30 
M in 20 mM phosphate buffer, pH 7.4 and immediately loaded into the cuvette for analysis. 
Scattering was measured every 2 minutes for the first hour, every 6 minutes for the following 2 
hours, and every 10 minutes for the subsequent 2 hours. All reported measurements are averages 
of 10 acquisitions. Trials with indistinguishable oligomer and larger aggregate peaks, or with poor 
fits, were disregarded in analysis. 
2.4.6. Nuclear Magnetic Resonance 
 All NMR spectra were obtained on a Bruker 600 MHz spectrometer (Bruker Corporation, 
Billerica, MA, USA). 300 L of peptide solution in 20 mM phosphate buffer pH 7.4 with 10% 
D2O (v/v) was prepared. Spectra were collected every two minutes at 25 ºC with a spectral width 
of 8992.8 Hz and 64 or 32 scans for the 30 M and 120 M samples, respectively. Spectra were 
processed using Topspin 2.1 (Bruker), where normalized oligomer peak intensities were 
determined via fixed bound integration.  
2.4.7. Pyrene Fluorescence Assay 
 Pyrene solutions were prepared by dissolving pyrene powder in DMSO followed by serial 
dilution down to 1 M in 20 mM phosphate buffer, pH 7.4. Samples were prepared by dilution of 
peptide stock to final peptide concentration in 20 mM phosphate buffer, pH 7.4, with 1 M pyrene 
to ensure constant pyrene concentration throughout titration/dilution. Pyrene emission spectra 
were recorded with a FluoroMax-4 Spectrofluorometer (Horiba, Ltd., Kyoto, Japan), with final 
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spectra being obtained via averaging of three scans taken at 25 ºC. Excitation was at 334 nm with 
a bandwidth of 2 nm, emission bandwidth was 1 nm. The intensities of peaks I and III were 
recorded at 370 nm and 381 nm, respectively. The I/III intensity ratio was plotted vs peptide 
concentration, and the CMC was determined by fitting the data to an inverse logarithmic decay 
and determining the point at which the ratio dropped beyond low concentration average. 
2.4.8. Kinetics Modeling 
 The kinetics modeling equations are given below. 
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In these equations, mi(t) and mn(t) represent the concentrations of hCT peptides before and after 
structure conversion, Pb(t) and Pn(t) represent the number concentration of growth-incompetent 
and growth-competent aggregates, and Mp(t) and Mf(t) represent the mass concentrations of 
protofibrils and mature fibrils, respectively. mtot represents the total concentration of hCT peptides 
in the system. It is noticeable that mtot = mi(t)+mn(t)+Mp(t)+Mf(t) due to the conservation law of 
mass. kmc, kfc, kn, kb
+, kb
-, ke, and kf are the rate constants governing the structure conversion of 
monomers and protofibrils, the primary nucleation of hCT monomers, the conversion from 
growth-competent to growth-incompetent aggregates by binding with pre-converted hCT 
monomers and its inverse reaction the growth of fibrils through elongation, and the fragmentation 
of protofibrils, respectively (Fig. 4A). nc represents the critical nucleus size for primary nucleation. 
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2.4.9. Molecular Dynamics Simulations 
 Molecular dynamics (MD) simulations were carried out for sequences representing hCT 
and sCT at neutral pH, hCT at pH 3, and a hCT mutant (T12L, F16L, F19L hCT). All sequences 
used methylated acetyl and methylated amide as blocking groups at the N- and C-termini, 
respectively (ACE and CT3 patches in CHARMM). The simulations were performed using the 
CHARMM software package and force fields.(79, 80) In order to sample the conformational 
distributions adopted by each peptide in solution, simulations were performed utilizing the replica 
exchange methodology and an implicit, generalized Born solvent model adopted to run on 
GPUs.(81, 82) The peptide was represented in an implicit (Debye-Hückel) ionic environment 
representing 100 mM NaCl.(83) All heavy atom – hydrogen bonds were constrained using the 
SHAKE algorithm, and the each temperature window of the replica exchange sampling was 
coupled to a Langevin temperature bath at the desired temperature.(84, 85) Twelve temperature 
windows, which were exponentially distributed between 310K and 400 K, were employed. Each 
replica was sampled for 100 ns, or a total sampling of 1.2 s. For each replica 5000 snapshots were 
saved at each temperature for subsequent analysis. The conformational distribution for each 
sequence was characterized at 310K by computing the distribution of structural characteristics, 
i.e., end-to-end distance, helical content and radius of gyration. Additionally, the ensemble of 
structures at 310K from each sequence was visualized by clustering the structures from replica-
exchange steps 1000-5000 using K-means clustering with 4.5 Å C + C rmsd based with the 
MMTSB Tool cluster.pl criterion.(86) 
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Chapter 3 
The role of phospholipid membranes in the amyloid aggregation of 
human calcitonin 
 
3.1 Introduction 
Since the discovery of its skeletoprotective effects, the 32-residue peptide hormone 
calcitonin (CT) has been used as a therapeutic for the bone-related diseases osteoporosis and 
Paget’s disease.(1–4) However, the propensity for human CT (hCT) to form amyloid fibrils limits 
its use as a therapeutic through the sequestration and remodeling of the monomeric peptide 
required for receptor activation and subsequent maintenance of bone mass.(5, 6) As such, the 
slower aggregating salmon CT (sCT) has replaced hCT as the current preferred CT peptide for 
therapeutic applications.(2, 7) Despite improvements in bioavailability and activity, sCT-based 
therapies are still limited by fiber formation, along with additional side effects like anorexia, 
vomiting, and immune responses.(4, 8–10) Studies have shown hCT therapies to be devoid of the 
negative side effects associated with sCT therapies, and have found hCT to exhibit improved 
biological activity under conditions where aggregation was controlled.(5, 7, 11) To date however, 
this kind of control has only been possible in vitro. There is thus significant interest in elucidating 
the factors which determine hCT aggregation kinetics, not only for improving therapeutic efforts, 
but to provide a better understanding of the general processes involved with amyloid aggregation. 
Recently, lipid-based nanoparticle delivery systems have been applied to fibrillating 
peptide therapeutics such as insulin and sCT.(12–19) A growing number of examples in the 
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literature have implicated lipid membrane interactions as key modulators of the aggregation of a 
range of fibrillating amyloids including amyloid-, islet amyloid polypeptide (IAPP), and -
synuclein.(20–26) Membranes have been shown to induce and stabilize multiple secondary 
structural motifs, slow and accelerate aggregation kinetics, provide scaffolds for amyloid 
association, and alter aggregation pathways.(21–24, 27–30) All these effects are modulated by 
membrane characteristics including composition, curvature, surface charge, phase, and 
microdomain architecture.(20–22, 31–37) Owing to this complexity, systematic studies to explore 
the effects of membranes on amyloid aggregation are needed.(21, 23, 33, 34) The CT field in 
particular has a need for such studies, as lipid-based delivery systems present a means to control 
aggregation pre-uptake and improve uptake without peptide modifications through intelligent 
choice of lipid membrane characteristics.(12, 14–17, 19, 38, 39) To date, few studies have looked 
at CT-membrane interactions, with even fewer reporting on the effects of membranes on 
aggregation kinetics.(40) 
Here, for the first time, the dependence of hCT aggregation on model membranes has been 
systematically studied using several biophysical techniques. In the presence of large unilamellar 
vesicles (LUVs) composed of several common phospholipids, Thioflavin-T (ThT) kinetic assays 
of hCT show a direct relationship between peptide concentration and lag time, in keeping with 
previous results observed in solution.(41) The magnitude of this concentration dependence varies 
with membrane charge and fluidity and appears to be heightened with more rigid and anionic 
phospholipid compositions that enhance surface interactions. Circular dichroism (CD) 
experiments suggest that this behavior is due to the adsorption of hCT to the membrane surface. 
Additionally, we see an apparent remodeling of amyloid fibers by LUVs, similar to a previous 
study on amyloid-.(30) This remodeling appears to be due to interactions between mature fibrils 
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and membranes and is dependent on the peptide to lipid ratio. Overall these results exhibit an 
inhibitory role for hCT-membrane interactions, and present useful information for understanding 
membrane mediated amyloid aggregation and the design of lipid-based CT delivery systems. 
3.2 Results and Discussion 
3.2.1. hCT displays a direct relationship between peptide concentration and lag phase 
through surface mediated peptide-membrane interactions 
In order to monitor aggregation in a membrane environment, hCT was allowed to aggregate 
in the presence of 100 nm diameter LUVs. The ease with which LUV compositions can be altered 
while maintaining a bilayer of consistent size and curvature allows the systematic study of the 
effect of membrane composition on hCT aggregation.(21, 42) The aggregation of both 10 M and 
40 M hCT was tracked in LUVs composed of DOPC, POPC, DOPC:DOPG (7:3 molar ratio) and 
POPC:POPG (7:3 molar ratio) using the ThT assay, a common method for detecting amyloid 
formation.(21, 30, 42–45) In all membrane compositions excluding DOPC, it was found that hCT 
showed a direct relationship between peptide concentration and lag time (Fig. 3.1). Such a result 
is consistent with previous studies on the aggregation of hCT in solution.(41) In that work it was 
found that the direct relationship was caused by plasticity in the hCT monomer leading to growth-
competent and growth-incompetent species, with growth competence being determined by -
helical secondary structural motifs. For additional details, please refer to Chapter 2.  
The induction of -helical structural motifs is a consistent feature of amyloid-membrane 
interactions.(22, 23, 27, 28, 46, 47) The energetic favorability of amphipathic helix association 
with both hydrophobic acyl chains and hydrophilic head groups could also explain the kinetic trend 
seen in the present study. While the induction of helical motifs by LUVs could increase the number 
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of growth-competent hCT monomers, interactions with the membrane could over-stabilize and 
isolate such monomers, thus decreasing their effective concentration, equivalent to a decrease in 
monomer conversion rate (kmc) as shown previously.(41) Given the presumed role of peptide 
sequestration by LUVs, one would expect lag time to be dependent on LUV concentration. Indeed, 
the addition of higher LUV concentrations was found to increase hCT lag times in a dose 
dependent manner, supporting the idea that hCT sequestration is responsible for the LUV 
dependence of lag times (Fig. 3.2). We note that the interaction between hCT and membranes 
could be monomer or oligomer based, as both play a role in monomer conversion.(41) The 
maintenance of -helical structures has been shown to delay hCT aggregation, thus stabilizing 
Figure 3.1. hCT exhibits a direct relationship between peptide concentration and lag phase in a membrane 
environment. hCT at 10 blackand 40 M (red) was allowed to aggregate in the presence of 100 M of 100 nm 
LUVs composed of A) DOPC, B) DOPC:DOPG (7:3), C) POPC, and D) POPC:POPG (7:3), as well as in solution 
(E). All LUVs with the exception of pure DOPC showed higher concentrations of hCT to aggregate slower, consistent 
with hCT solution behavior. The difference between low and high peptide concentration lag times are dependent on 
membrane composition, with the addition of anionic lipids and increase in membrane transition temperature increasing 
the difference. Note the loss of signal intensity after elongation for 10 M hCT. This phenomenon is discussed further 
in Section 3.2.2. Displayed curves represent normalized averages of three independent trials at 25 °C in 20 mM 
phosphate buffer and 100 mM NaCl, pH 7.4.  
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interactions between growth-competent monomers and the membrane are likely responsible for 
our observed trend.(7, 41, 48–51)  
Both the addition of anionic lipids and a shift to more saturated acyl chains increase the 
dependence of lag time on concentration. These alterations would both be expected to promote 
surface interactions between lipid bilayers and amyloid peptides. Amyloids including hCT 
consistently show an affinity for anionic lipids regardless of peptide charge, and less fluid bilayers 
provide tighter packed lipids that would restrict peptide insertion.(20–22, 52, 53) Initial 
experiments show enhanced concentration dependent differences in lag time in more rigid DMPC 
LUVs (transition temperature of 24 °C as compared to -2 °C for POPC and -17 °C for DOPC), but 
further experiments are needed to confirm this behavior (Fig. B.1.).  
The idea of increased lag times being caused by stronger interactions between amyloid 
peptides and the membrane surface specifically is consistent with several previous amyloid-
membrane kinetics studies.(21, 34, 35, 40) A previous study on hCT-membrane interactions found 
Figure 3.2. DOPC and POPC LUVs slow hCT aggregation in a dose dependent manner. hCT at 40 M was allowed 
to aggregate in solution (black) and in the presence of 100 M (red) and 400 M (blue) of 100 nm LUVs composed 
of A) DOPC and B) POPC. For both membrane compositions, LUVs slowed fiber formation in a dose-dependent 
manner, indicating inhibition of fiber formation through peptide-membrane interactions. Displayed curves represent 
normalized averages of three independent trials at 25 °C in 20 mM phosphate buffer and 100 mM NaCl, pH 7.4 
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that the rigidification of membranes by cholesterol inhibited peptide insertion, and instead forced 
membrane-surface mediated aggregation and fibril mat formation.(40) ThT experiments with 
amyloid-have shown smaller vesicles to accelerate aggregation, and more rigid membranes were 
found to slow the aggregation of hIAPP.(21, 34, 35) In both cases, the diminished exposure of 
hydrophobic patches and enhanced surface interactions were found to delay aggregation, 
consistent with surface interactions between helical hCT and LUVs being the driving force in the 
observed kinetic trend in this study.  
In order to further explore this hypothesis, time-course CD experiments were performed 
for the four LUV compositions shown in Figure 3.1. Interestingly, the results were found to 
contrast with the ThT-detected kinetics, in that hCT lost its initial random coil signal more slowly 
in conditions shown to aggregate faster by ThT (Fig. 3.3). However, this loss of random coil signal 
was not correlated with a subsequent gain of -sheet signal, indicating the decline to be 
independent of fibril formation. A probable explanation for this signal loss over time is the 
phenomenon of absorption flattening. This process occurs when particles dispersed with LUVs in 
solution localize to the membrane surface, leaving some regions enriched and others depleted in 
particles resulting in the breakdown of the Beer-Lambert Law and subsequent intensity loss (Fig. 
B.2).(54) We note that no signal loss is seen with the weakly interacting DOPC LUVs in the first 
three hours, despite DOPC being the fastest aggregating condition by ThT, further supporting the 
hypothesis that signal loss is caused by peptide-membrane interactions and subsequent absorption 
flattening rather than aggregation.(55, 56) The observation of this phenomenon in our CD 
experiments with the most rapid CD signal loss occurring in the slowest aggregating conditions 
supports the idea that differential rates of hCT association with LUVs are responsible for retarded 
aggregation. 
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CD spectra taken at intermediate time points in all four LUV conditions show the slower 
aggregating PO lipids to have a lower signal intensity as well as increased helical content (Fig. 
B.3). Such results are consistent with the idea that adsorption and stabilization of helical monomers 
of hCT causes an increase in lag time. CD experiments evaluating the differences between DMPC 
and DOPC LUVs appear consistent with this trend, but again further experiments are needed to 
confirm this behavior (Fig. B.4). Additionally, CD spectra taken after 24 hours of aggregation are 
predominantly -sheet, implying the initial flattening to represent one of the first steps along the 
Figure 3.3. Differential absorption flattening in time-course CD experiments indicate different rates of peptide 
adsorption. CD spectra of hCT at 40 M were collected at the indicated time points with 100 M of 100 nm LUVS of 
A) DOPC, B) DOPC:DOPG (7:3), C) POPC, and D) POPC:POPG (7:3). The decreased intensity of the random coil 
peak at 200 nm over time is fastest for the slower aggregating samples. Signal loss occurs without the appearance of 
new peaks, suggesting spectral changes to be due to absorption flattening rather than peptide remodeling. Samples 
were prepared identically to those used for ThT experiments with the exception of NaF replacing NaCl. All 
measurements and incubations were performed at 25 °C. 
89 
 
fibrillation pathway rather than an uncorrelated amorphous aggregation (Fig. B.5). Taken together, 
the current ThT and CD results indicate that the adsorption of monomers of hCT onto the surface 
of LUVs delays aggregation and leads to composition dependent differences in the relationship 
between lag time and concentration. However, further experiments are needed to further elucidate 
the observed behavior and confirm the relevant species in determining LUV-mediated kinetics. 
Interestingly, 10 M hCT concentration kinetics seem relatively unaffected by lipid 
composition, with the major changes in lag time concentration dependence being due to 40 M 
hCT conditions (Fig. B.6). In the previous study, lower concentrations of hCT exhibited smaller 
and shorter lived oligomeric species immediately after peptide dissolution, with such differences 
playing a role in lag time determination.(41) It is speculated that a possible explanation for the 
relative independence of 10 M hCT lag time from lipids has to do with these differences in 
oligomeric reformatting. If interactions between hCT and the membrane are influenced by 
oligomers, as has been previously shown for hCT and other amyloids, the transience of low 
concentration oligomers could serve to limit these interactions and by extension the effect of lipid 
composition on lag time.(29, 37, 57–63) Furthermore, the sequestering behavior of hCT-LUVs 
interactions would be expected to have a diminished effect on 10 M hCT as opposed to 40 M, 
given that the lower concentration already experiences fewer peptide-peptide interactions. One or 
both of these mechanisms could be responsible, but further experiments are needed to better 
elucidate the cause of this phenomenon. 
3.2.2. LUVs show an ability to remodel fibers of hCT in a peptide to lipid ratio dependent 
manner 
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Typically, mature amyloid fibers are highly stable, and require the introduction of 
significant molecular, chemical, or mechanical stresses to undergo remodeling.(64–69) This 
stability is reflected in the flat plateau phase of ThT fluorescence curves where the amount of -
sheet structure is constant. However, as can be seen in Figure 3.1., after reaching maximal 
fluorescence intensity, 10 M samples of hCT then exhibit a decline in fluorescence intensity 
rather than the characteristic plateau. Previous studies on ThT-amyloid interactions have shown 
hydroxylation to cause a decline in fluorescent signal, especially under basic conditions.(70) 
However, the disparity between intensity loss in fibrils grown in the presence of LUVs and fibrils 
grown in solution, along with the LUV dependence of the signal decay, suggests the signal loss to 
be due to peptide-LUV interactions (Fig. B.6).  
The presence of remodeling at 10 M hCT and not 40 M hCT raises the question of 
whether the cause was concentration dependent differences in aggregate morphology or 
inconsistent peptide to lipid ratio. By increasing LUV concentration from 100 to 400 M, and thus 
maintaining the same peptide to lipid ratio, we were able to see signal loss in 40 M hCT 
conditions, indicating this trend to be dependent on the peptide to lipid ratio rather than overall 
peptide concentration (Fig. 3.4). Additionally, as with 10 M hCT in the presence of 100 M 
LUVs, the decline of 40 M hCT conditions is more rapid and pronounced in the presence of 
DOPC lipids as opposed to POPC lipids. Initial experiments also suggest that higher temperatures 
(35 °C) induce remodeling, but further experiments are needed to confirm this behavior (Fig. B.7). 
Amyloid fiber growth can proceed along different pathways in lipid bilayers as compared 
to in solution, with such differences potentially leading to distinct polymorphs.(23, 24, 26, 35, 64, 
71) The more rapid decline with DOPC as compared to POPC also suggests that polymorphs 
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grown in different LUV solutions could explain the differences in fibril stability. In order to 
determine whether or not hCT fiber morphologies grown in the presence of our model membranes 
were less stable, we tested the ability of LUVs to remodel mature fibrils grown in solution. Upon 
the introduction of LUVs to solution grown fibrils, the previously stable ThT signal was found to 
decrease in a manner similar to fibrils grown with LUVs (Fig. 3.5). The addition of DOPC LUVs 
resulted in a rapid decrease, while the introduction of POPC resulted in a slower and smaller 
decrease, consistent with the remodeling seen in LUV-grown fibers (Fig. 3.4, Fig. B.6). 
Noteworthy is the fact that the introduction of DOPC LUVs remodeled both the 10 M and 40 M 
fibers samples, whereas POPC LUVs could only remodel the 10 M sample. Combined with the 
results shown in Figures 3.4 and B.6, this suggests DOPC-mediated remodeling of hCT fibrils to 
be more efficient. More significantly, the fiber remodeling is not dependent on the fiber growth 
Figure 3.4. Remodeling of hCT fibers depends on peptide to lipid ratio. hCT at 40 M was allowed to aggregate in 
the presence of 100 M and 400 M of 100 nm LUVs composed of DOPC and POPC. Fibers formed in the presence 
of 100 M LUVs maintain a stable ThT signal, whereas fibers in the presence of 400 M LUVs showed signal loss. 
DOPC LUVs also induced more rapid and significant loss of ThT signal as compared to POPC LUVs. Displayed 
curves are normalized averages of three independent trials at 25 °C in 20 mM phosphate buffer and 100 mM NaCl, 
pH 7.4. 
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conditions, suggesting instead that the relevant interactions are between mature fibers and lipid 
bilayers. 
The remodeling of mature amyloid fibers by lipid bilayers has been previously observed in 
amyloid-albeit with much more lipid specificity.(30)  LUVs of the phospholipid DLPC were 
found to convert long fibrils of amyloid- into shorter, ThT-negative amorphous aggregates. This 
unique behavior of DLPC was presumed to arise from its smaller hydrophobic thickness as 
compared to other phospholipids studied. Such an explanation seems unlikely for the present study, 
as the bilayer thicknesses of DOPC (26.8 Å) and POPC (27.1 Å) are similar.(72) This disparity, 
along with the different peptide and lipids used, means the remodeling observed in this study is 
likely a different mechanism. Additionally, the remodeling observed in this study could represent 
either changes in overall fibril architecture or changes in ThT-fiber interactions. ThT-negative 
amyloid fibers and ThT signal loss caused by small molecules leaving fibrils intact have both been 
previously reported, and we caution against the overinterpretation of ThT kinetics assays.(73, 74) 
Figure 3.5. LUVs are capable of remodeling solution-grown hCT fibrils. hCT fibrils at 10 and 40 M were grown 
in solution until fibril population was stable by ThT, at which point LUVs were introduced (black arrow). The 
introduction of DOPC LUVs (A) led to immediate decrease in ThT signal for 10 and 40 M hCT. In contrast, 
POPC LUVs (B) caused smaller and slower signal loss at 10 and no signal loss at 40 M. The heightened potency 
of DOPC LUVs to remodel fibers as compared to POPC LUVs is consistent with results for fibrils grown with LUVs 
(Fig. 3.4). Displayed curves represent normalized averages of three independent trials at 25 °C in 20 mM phosphate 
buffer and 100 mM NaCl, pH 7.4. 
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Future experiments to determine the nature of fibril remodeling observed in this study are needed 
to fully characterize the effect. The fluorescent dye bis-ANS has been previously used to detect 
amyloid fibers, and would help clarify if the observed signal loss was a ThT specific 
phenomenon.(75) TEM images of fibers before and after the addition of LUVs may provide an 
answer as to the degree of fiber remodeling, as any macroscopic changes in fibril morphology 
could be visible, and the Bradford assay could help determine the degree of protein resolubilization 
by LUVs, giving additional information towards the development of a more quantitative picture 
of fibril remodeling.(76, 77) 
3.3. Conclusions 
In this study, the aggregation of hCT in the presence of lipid bilayers was systematically 
studied for the first time. hCT was found to show a direct relationship between peptide 
concentration and lag time in a membrane environment, similarly to previously reported results in 
solution. The extent of this concentration dependence was found to depend on membrane 
composition, with LUVs encouraging surface interactions leading to larger concentration 
dependences. Comparative CD experiments showed enhanced adsorption rates of hCT to correlate 
with retarded aggregation, implicating the over stabilization of helical structures and peptide 
sequestration as causative in the trend. The degree of inhibition was found to not simply depend 
on membrane composition, but also on peptide and lipid concentration. Finally, LUVs showed an 
ability to remodel mature fibrils of hCT, whether grown in solution or a membrane environment. 
This remodeling was found to depend both on membrane composition and on peptide to lipid ratio. 
These results suggest that lipid nanoparticles for therapeutic delivery should use compositions that 
encourage surface interactions, specifically through the use of anionic and higher transition 
temperature lipids. Such choices of lipids represent a simple and non-perturbative way to delay 
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aggregation and maintain soluble peptide hormone without peptide modifications. This study will 
serve to improve our understanding of how amyloid-membrane interactions can mediate 
aggregation, and future directions could further inform lipid-based peptide therapeutic delivery 
systems. 
3.4. Materials and Methods 
3.4.1. Peptide preparation 
Human calcitonin peptide was synthesized via Fmoc chemistry as described 
previously.(78) The disulfide bond between Cys1 and Cys7 of hCT was formed by air oxidation 
at pH 8.0-8.5 at diluted concentration and in the presence of 6 M urea to prevent fibrillation. To 
ensure consistent monomeric starting conditions, peptide was dissolved in hexafluoroisopropanol 
(HFIP) at a concentration of 1 mg/ml. Peptide was then separated into 100 L aliquots, flash frozen 
in liquid nitrogen, and lyophilized for a period of 48 hours. After lyophilization, peptide aliquots 
were stored at -80 ºC until use. Peptide solutions were prepared by resolubilizing the lyophilized 
aliquots in 100 L of HCl pH 4 at 4 °C to a concentration of ~300 M, followed by brief sonication 
to ensure peptide dissolution. Peptide solutions were then warmed to room temperature and 
subsequently used.  
3.4.2 Vesicle preparation 
1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-
glycero-3-phospho-(1'-rac-glycerol) (DOPG), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
(1'-rac-glycerol) (POPG) lipids were purchased from Avanti Polar Lipids Inc. (Alabaster, AL, 
USA). Large unilamellar vesicles (LUVs) were prepared of pure DOPC, POPC, and DMPC, as 
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well as mixtures of DOPC:DOPG and POPC:POPG in 7:3 molar ratios. Appropriate lipid 
compositions were prepared in chloroform and dried under nitrogen, and the resultant films were 
lyophilized overnight to remove residual solvent. Lipid films were rehydrated with buffer (20mM 
phosphate, 100mM NaCl, pH 7.4) to a final concentration of 1 mM. The resultant suspension was 
mixed to ensure complete film resolubilization, and subsequently extruded 21 times through 100 
nm polycarbonate Nucleopore membrane filters (Whatman) mounted on a mini-extruder (Avanti 
Polar Lipids Inc.). The formation of a homogeneous population of 100 nm vesicles was confirmed 
via dynamic light scattering.  
3.4.3. Thioflavin-T Kinetic Assay 
Thioflavin-T (ThT) experiments were run on a Biotek Synergy 2 microplate reader 
(BioTek Instruments, Inc., Winooski, VT, USA) on uncoated Fisherbrand 96-well polystyrene 
plates. Peptide was added to final concentrations of 20 mM phosphate buffer, 100 mM NaCl, pH 
7.4 and ThT, and immediately prior to acquisition. Experiments were performed in triplicate with 
two equivalents of ThT and 70 L total volume. Wells were bottom read with an excitation 
wavelength of 440 nm (30 nm bandwidth) and emission wavelength of 485 nm (20 nm bandwidth). 
Fibril remodeling ThT assays were performed by adding 3.68 L of 2 mM LUV stocks to the 70 
L total sample volume, to yield final LUV concentrations of 100 M. An equivalent volume of 
buffer was added to control wells. 
3.4.4. Circular Dichroism 
Circular dichroism (CD) spectra were taken on a Jasco J-1500 Circular Dichroism 
Spectrometer (JASCO, Inc., Easton, MD, USA). Spectra were recorded with 40 M hCT in 20 
mM phosphate buffer, 100 mM NaF, pH 7.4 in a 1 mm quartz cuvette. Spectra were recorded with 
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2 nm bandwidth, 1 nm step size, scan speed of 100 nm/min, baseline corrected, and averaged over 
5 scans. Smoothing was performed using the Savitzky-Golay method, with a convolution width of 
15. Between reads, peptide samples were transferred to a microcentrifuge tube and shaken at ~500 
rpm at the same temperature as spectra collection unless otherwise indicated. 
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70.  Foderà, V., Groenning, M., Vetri, V., Librizzi, F., Spagnolo, S., Cornett, C., Olsen, L., van 
de Weert, M., and Leone, M. (2008) Thioflavin T Hydroxylation at Basic pH and Its 
Effect on Amyloid Fibril Detection. J. Phys. Chem. B. 112, 15174–15181 
71.  Chiti, F., and Dobson, C. M. (2017) Protein Misfolding, Amyloid Formation, and Human 
Disease: A Summary of Progress Over the Last Decade. Annu. Rev. Biochem. 86, 27–68 
72.  Kučerka, N., Tristram-Nagle, S., and Nagle, J. F. (2006) Structure of Fully Hydrated Fluid 
Phase Lipid Bilayers with Monounsaturated Chains. J. Membr. Biol. 208, 193–202 
73.  Wong, A. G., Wu, C., Hannaberry, E., Watson, M. D., Shea, J.-E., and Raleigh, D. P. 
(2015) Analysis of the Amyloidogenic Potential of Pufferfish (Takifugu rubripes) Islet 
Amyloid Polypeptide Highlights the Limitations of Thioflavin-T Assays and the 
Difficulties in Defining Amyloidogenicity. Biochemistry. 55, 510–518 
74.  Kroes-Nijboer, A., Lubbersen, Y. S., Venema, P., and van der Linden, E. (2009) 
Thioflavin T fluorescence assay for β-lactoglobulin fibrils hindered by DAPH. J. Struct. 
Biol. 165, 140–145 
75.  Younan, N. D., and Viles, J. H. (2015) A comparison of three fluorophores (ThT, ANS, 
bis-ANS) for the detection of amyloid fibers and prefibrillar oligomeric assemblies. 
Biochemistry. 54, 4297–4306 
76.  Harlow, E., and Lane, D. (2006) Bradford Assay. Cold Spring Harb. Protoc. 2006, 
pdb.prot4644-prot4644 
77.  Ku, H.-K., Lim, H.-M., Oh, K.-H., Yang, H.-J., Jeong, J.-S., and Kim, S.-K. (2013) 
Interpretation of protein quantitation using the Bradford assay: Comparison with two 
calculation models. Anal. Biochem. 434, 178–180 
78.  Huang, R., Vivekanandan, S., Brender, J. R., Abe, Y., Naito, A., and Ramamoorthy, A. 
(2012) NMR characterization of monomeric and oligomeric conformations of human 
calcitonin and its interaction with EGCG. J. Mol. Biol. 416, 108–20 
103 
 
Chapter 4 
Conclusions and Perspectives 
4.1. General Conclusions  
Amyloid aggregation remains a poorly understood biological process, despite its ubiquity 
and the breadth of scientific efforts to understand it. The complexity of the process, particularly in 
the early stages with several metastable and heterogeneous species, likely has obfuscated certain 
pathways and features of the amyloid cascade. The study of CT holds the potential to elucidate 
previously undetected amyloid aggregation pathways, as well as providing information valuable 
in improving its activity as a therapeutic. While early events in hCT aggregation have received 
more attention recently, as with all amyloid peptides, further studies are required before a 
functional understanding of the aggregation intermediates can be constructed.(1–4) The results of 
this thesis provide new insights into the aggregation of hCT in both solution and membrane 
environments, and have the potential to inform future efforts to influence amyloid aggregation in 
both hCT and other amyloids.  
 In Chapter 2, a novel direct relationship between initial monomer concentration and lag 
time for hCT was demonstrated for the first time, in contrast to previous results in the amyloid 
literature. ThT kinetic assays revealed this trend to exist in a range of aggregation environments, 
and the differential rates in fibril formation were confirmed by CD and TEM measurements. The 
micelle-like oligomers detected in hCT do not influence its aggregation kinetics, unlike the strong 
effects reported for similar oligomers in other amyloids.(5–9) Seeded ThT assays along with DLS 
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and solution NMR results suggested an origin for the aggregation behavior in the early steps of 
aggregation. Kinetic modeling provided a novel aggregation mechanism whereby monomer 
conformation conversion and subsequent inhibition slows aggregation in a concentration 
dependent process. hCT at low pH and sCT were both found to show the canonical inverse 
relationship between peptide concentration and lag time. MD simulations comparing hCT and sCT 
suggest that relative levels of helical secondary structure distinguish growth-competent and 
growth-incompetent monomers, explaining the differences in the peptide concentration versus lag 
time relationship between hCT and sCT. These results suggest that small structural elements in the 
mostly unstructured monomers of CT are necessary for fibril formation and crucial in determining 
aggregation kinetics. Further, the kinetic model represents a novel aggregation pathway, and 
synthesizes several previously disparate phenomenon into one cogent mechanism, while still 
incorporating the canonical nucleation-elongation-fragmentation kinetic model of Knowles and 
colleagues.(10–18) Future efforts to ascertain a more detailed structural understanding of this 
atypical behavior of hCT and overcome the difficulties inherent in detecting such monomeric 
reformatting in the heterogeneous amyloid environment are needed to fully characterize the 
aggregation process.  
 In Chapter 3, the first study of the effects of model membranes on hCT aggregation kinetics 
was performed. Using LUVs composed of several different common phospholipids, it was found 
that hCT maintained its direct relationship between peptide concentration and lag time 
independently of membrane composition. The quantitative difference between low and high 
concentration lag times varied with membrane composition, with lipid compositions encouraging 
stronger surface interactions most significantly retarding aggregation. CD showed slower 
aggregating conditions to correspond with more significant partitioning of hCT to the membrane 
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surface. Combining this with previously known interactions of amyloids with membranes, a 
mechanism is proposed whereby surface interactions pull helical growth-competent monomers off 
pathway, thus depleting the population of monomers able to aggregate and delaying fibrillation. 
LUVs also showed an ability to remodel hCT in both a membrane composition and peptide to lipid 
ratio dependent manner. This behavior is reminiscent of a previously reported behavior of DLPC 
LUVs with the amyloid-peptide, and hints that this phenomenon could be more general than 
previously believed.(22)  
 These results help to address several questions in the amyloid and CT therapeutic fields. 
The results from Chapter 2 highlight the importance of monomer structure and intramolecular 
interactions in the amyloid aggregation of intrinsically disordered peptides, which has been an area 
of controversy in the amyloid field.(11, 19–21) The relative transience of intramolecular forces 
compared to intermolecular forces, especially in intrinsically disordered peptides, has relegated 
the former to an afterthought in considering mediators of aggregation kinetics, a viewpoint which 
will hopefully be reformed by these results.  Given the desire for oral delivery of CT therapeutics, 
and the early promise of lipid-based delivery systems, the composition- and concentration-
dependent modulation of hCT aggregation kinetics by lipid membranes shown in Chapter 3 is of 
interest for therapeutic development. The trends discovered provide valuable guidance in 
intelligently designing lipid-based delivery system to enhance bioavailability and limit pre-uptake 
aggregation, thus improving therapeutic efficacy. Additionally, the remodeling results in Chapter 
3 are in contrast to the typical picture of membrane assisted amyloid aggregation, where 
membranes can influence kinetics and morphology but play a limited role once the mature stable 
fibers are formed.(21, 23–28) This behavior points to a richer picture for amyloid fibril-membrane 
interactions, and could bear relevance to the development of amyloid associated pathologies 
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through novel secondary nucleation and fragmentation pathways. Further work would be required 
however to gauge the biological and pathological relevance of this reformatting.  
4.2. Future Directions 
 While the work presented in this thesis provides new information on mechanisms of 
amyloid aggregation both in solution and in the membrane, the complexity and heterogeneity of 
the aggregation process presents numerous opportunities for further study. In both Chapter 2 and 
Chapter 3, helical motifs in hCT monomers were suggested to play a major role in determining 
aggregation kinetics and the relationship between peptide concentration and lag phase. As such, 
the induction of helical structure in hCT presents a way to further evaluate the role of such motifs 
in aggregation. The addition of 2,2,2-trifluoroethanol (TFE) has the ability to dose-dependently 
induce enhanced helical structure in the monomeric peptide, granting some control over the 
monomeric structure and allow for a more systematic analysis on the role of -helical monomers 
in hCT aggregation.(29–31) Further, mutation studies with hCT have yielded slower aggregating 
and more stable -helical mutants that could experimentally elucidate the specific residues or 
regions that are key for determining hCT monomer growth-competence and the dependence of lag 
time on concentration.(14, 32–34)  
 Additionally, while helical monomer motifs appear to be key mediating factors in the 
aggregation of hCT, it remains undetermined whether or not this is unique to hCT or a general 
property for all amyloids. While helical intermediates have been demonstrated in a number of other 
amyloids, it remains unclear what roles these intermediates play in influencing monomer growth-
competence and aggregation.(26, 35–46) For example, the formation and stabilization of helical 
monomers of -synuclein by membrane mimetics has been shown to both accelerate and delay 
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aggregation, calling into question the generality of the trends presented in this dissertation.(47–49) 
By repeating the experiments in Chapter 2 and 3 in other model amyloids such as IAPP, amyloid-
, and -synuclein, and exerting control over their helical propensity, the applicability of our 
kinetic mechanism to other amyloids in solution and in the presence of membrane could be 
explored. Considering the toxicity of oligomeric intermediates and the struggles currently faced in 
their characterization, the prospect of identifying key aggregation modifiers at the monomer level 
provides an attractive alternative for drug targets. 
 Given the presumed importance of interactions between helical hCT and the membrane 
surface presented in Chapter 3, future studies aimed at interrogating this behavior at a higher 
structural resolution are crucial. The field of NMR spectroscopy provides a number of techniques 
well suited to the study of membrane bound amyloids, even in unlabeled peptides. Line broadening 
in 1H NMR spectra of hCT in the presence of LUVs would provide further confirmation of peptide 
adsorption, and transferred 1H–1H nuclear Overhauser effect spectroscopy (tr-NOESY) would 
allow direct confirmation of the degree of structure present in bound hCT populations, given the 
likelihood of exchange between the bound and free form.(50–52) Due to the slow tumbling speed 
of LUVs however, NMR spectra of membrane-associated peptides experience significant signal 
broadening due to longer correlation times, limiting the number of applicable experiments. 
Smaller, NMR-suitable membrane mimetics have typically required the incorporation of 
detergents or short chain lipids, which can interfere with the native peptide behavior.(53–56) 
Recent advances in membrane mimetics systems have given rise to small lipid bilayer patches 
called nanodiscs that tumble on the NMR timescale and form without detergents.(57, 58) 
Nanodiscs thus are ideally suited for structural characterizations of membrane bound hCT species 
through solution-state NMR methods, as has been demonstrated.(59–61) The use of nanodiscs with 
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NMR spectroscopy presents a new tool to probe amyloid-membrane interactions in a native 
environment, and could greatly improve our understanding of the role the membrane plays in 
influencing the early stages of amyloid aggregation.  
 Chapter 3 also demonstrated an ability for LUVs to remodel mature amyloid fibers of hCT, 
but relatively little is known about this behavior. The loss of ThT signal does not necessarily imply 
a loss of overall fiber structure, and could rather be reflective of side chain remodeling and 
subsequently reduced ThT binding. TEM provides a straightforward way to compare fibers before 
and after reformatting to determine the extent and nature of fibril structure loss. The clear 
differences in reformatting between DOPC and POPC lipids along with the enhanced remodeling 
seen at higher temperatures suggests membrane fluidity to play a crucial role in fibril reformatting. 
ThT experiments with more rigid DMPC LUVs, along with other LUVs incorporating anionic 
lipids would help confirm and discover additional mediators of this behavior. Comparative solid-
state HSQC NMR experiments on labeled hCT during reformatting would allow for the 
determination of residue specific insights into the reformatting process. Given previous studies, 
the remodeling of mature amyloid fibrils by model membranes could represent a more general 
phenomenon than previously believed.(22) Residue specific information on this behavior could 
not only elucidate previously unknown structural features in amyloid fibrils in a membrane system, 
but also inform the design of novel amyloid inhibitors. 
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Appendix A 
Supporting Information for Chapter 2 
 
A.1. Supplementary Figures 
 
Figure A.1. ThT fluorescence curves of hCT aggregation for TEM. ThT assay conditions identical to those for Figure 
2.1. Arrows indicate time point of removal of samples for TEM. Initial removal for both samples corresponds to t = 
15 mins for both conditions. Discontinuities arise from removal of sample from wells/disturbance of solution. 
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Figure A.2. Seeded ThT assays reveal lag time to not be entirely primary nucleus dependent. ThT assay conditions 
identical to those for Figure 2.1. A) Varying of seed percentage by volume with fixed hCT monomer concentration 
shows dose-dependent decrease of lag time with seed concentration, but does not show full abolition of lag time. B) 
Varying of hCT monomer concentration with fixed 10% seed by volume shows decrease in lag time versus pure 
monomer. The relationship between monomer concentration and lag time from the unseeded experiments is lost with 
seeding. 
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Figure A.3. DLS measurements show no time- or concentration-dependent differences in mass distribution over time 
between peaks. Both 120 µM and 30 µM DLS time course experiments show constant and equivalent percentage of 
total peptide mass in small oligomer peak (Fig. 2.3.A, peak I, shown above). Remaining peptide mass is contained in 
larger aggregate peak (Fig. 2.3.A, peak II). As would be expected early in the aggregation process, the majority of 
peptide mass is still in smaller oligomeric aggregates. 
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Figure A.4. Predictions on (a) fraction of monomers, (b) normalized number concentration of protofibrils, and (c) 
normalized mass concentration of protofibrils (all with respect to total hCT peptide concentration) under different 
initial hCT peptide concentration based on the kinetic model.  
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Figure A.5. The influence of reaction rate constants on the lag time of hCT fibrillation. In each group, the relative 
change of lag time is drawn when the marked rate constant is varied independently by one or two orders of magnitude 
higher or lower with respect to its default values given in the main text. The initial hCT peptide concentration is taken 
as 40 µM.  
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Figure A.6. Local sensitivity analysis on reaction rates. Let Y(t) = (𝑚i, 𝑚𝑛 , 𝑃n, 𝑃b, 𝑀p, 𝑀f) and K(t) =
(𝑘𝑚𝑐 , 𝑘𝑓𝑐 , 𝑘𝑛 , 𝑘𝑒 , 𝑘𝑓 , 𝑘𝑏
+, 𝑘𝑏 
−). Then the relative local sensitivity of Y with respect to K drawn in each subplot is defined 
as S(Y; K) =
𝐾
𝑌𝑚𝑎𝑥
𝑑𝑌
𝑑𝐾
. Here 𝑌𝑚𝑎𝑥 = max {𝑌(𝑡)|𝑡 ≥ 0} is adopted instead of Y in order to avoid singularities in Y. Based 
on local sensitivity analysis, following conclusions could be reached, i.e. i) 𝑚i mainly depends on 𝑘𝑚𝑐; ii) 𝑚n mainly 
depends on 𝑘𝑏
+; iii) 𝑀p 𝑎𝑛𝑑 𝑀f depend not only on 𝑘𝑓𝑐, but also on 𝑘𝑚𝑐 , 𝑘𝑒  in an indirect way; iv) 𝑃n and 𝑃b not only 
depend on 𝑘𝑛 , 𝑘𝑓, but also are influenced by all parameters; vi) 𝑘𝑏 
–  has no apparent effect on Y. 
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Figure A.7. sCT displays lower structural heterogeneity and inreased helical content when compared to hCT, with 
mutations to the aromatic residues in hCT and hCT at low pH inducing a more sCT-like behavior. A) Relative 
probability of hCT, sCT, hCT-mutant, and hCT (low pH) monomer conformations versus cluster number. sCT 
monomers sample a smaller section of conformational space than hCT, while mutated and low pH hCT occupy an 
intermediate amount of conformational space. B) sCT shows higher propensity for helical content than hCT, with 
mutated and low pH hCT showing intermediate levels of helical secondary structure. C) Radius of gyration and D) 
end-to-end distance values in monomer clusters for hCT, sCT, hCT mutant, and hCT at pH 3. sCT shows a sharper 
distribution with lower average radius of gyration when compared with hCT. sCT also has a lower average end to end 
distance, while showing distinct peaks in the end-to-end distances distribution, indicating its existence in several 
discreet clusters/conformations. Our hCT mutant and hCT at low pH behave in a more sCT like way. In particular, 
mutant hCT becomes significantly more favorable for compact structures as indicated by the increased probability for 
short end to end distances and radii of gyration. 
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Figure A.8. TEM image of 120 µM hCT aggregates in late lag phase (same sample as Fig. 2.1.). Image shows the 
presence of a number of punctate, proteinaceous aggregates presumed to be micelle-like oligomers, due to their shape, 
size, and presence only above the CMC. Aggregates appear to be ~20 nm in size, with relatively uniform size 
distribution. Aggregates don’t show any preference for or association with protofibrillar or fibrillar species. 
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Supporting Information for Chapter 3 
 
B.1. Supplementary Figures 
 
Figure B.1. LUVs with higher transition temperatures induce correspondingly larger concentration dependent 
increases in lag time. hCT at 10 and 40 M was allowed to aggregate in the presence of 100 M of 100 nm LUVs 
composed of A) DOPC, B) POPC, and C) DMPC. Moving to LUVs with higher transition temperatures leads to 
greater differences between low and high concentration lag times and slower aggregation. Due to the high transition 
temperature of DMPC (24 °C), experiments were run at 35 °C to ensure all LUVs were in the same phase. Increased 
temperature was found to accelerate aggregation under all conditions, and also remove concentration dependent 
differences in aggregation rate in solution (D). Displayed curves represent normalized averages of three independent 
trials in 20 mM phosphate buffer and 100 mM NaCl, pH 7.4. 
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Figure B.2. CD absorbance over time confirms absorption flattening and signal loss. Absorption spectra of hCT at 40 
M were collected at the indicated timepoints with 100 M of 100 nm LUVS of A) DOPC, B) DOPC:DOPG (7:3), 
C) POPC, and D) POPC:POPG (7:3). The rate of absorption loss is consistent with CD signal loss seen in Figure 3.3, 
indicating signal loss to be due to absorption flattening rather than peptide remodeling. Samples were prepared 
identically to those used for ThT experiments with the exception of NaF replacing NaCl. All measurements and 
incubations were performed at 25 °C. 
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Figure B.3. LUVs that slow aggregation increase adsorption and induce enhanced helical structure in hCT at 
intermediate time points. CD spectra of hCT at 40 M were collected after three hours of incubation with 100 M of 
100 nm LUVS of the indicated lipid compositions under 1000 rpm shaking. The faster aggregating DO lipid conditions 
show higher intensity and greater random coil propensity when compared to the slower aggregating PO lipids, which 
show a stronger helical propensity. This difference is quantified in the table showing the ratio between helical signal 
at 222 nm and random coil signal at 200 nm. The increased absorption flattening and helical propensity indicate the 
enhanced stabilization of growth-competent hCT monomers by PO lipids as compared to DO lipids. Samples were 
prepared identically to those used for ThT experiments with the exception of NaF replacing NaCl. All measurements 
and incubations were performed at 25 °C. 
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Figure B.4. DMPC LUVs show more rapid absorption flattening and induce greater helical structure in hCT than 
DOPC LUVs. CD spectra of 40 M hCT were collected at the indicated timepoints in 100 M of 100 nm LUVs of A) 
DOPC and B) DMPC. Signal loss is more rapid for DMPC LUVs, again consistent with the idea that more rigid 
bilayers encourage surface interactions and faster absorption flattening. C) The CD spectra for DOPC and DMPC at t 
= 3hr show weaker signal intensity and enhanced helical propensity for DMPC, consistent with similar comparisons 
between DO and PO lipids. The faster loss of CD signal as compared to Figure 3.2. is due to the overall aggregation 
acceleration at 35 °C compared with 25 °C. Samples were prepared identically to those used for ThT experiments with 
the exception of NaF replacing NaCl. All measurements and incubations were performed at 35 °C. 
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Figure B.5. CD spectra taken after 24 hours of aggregation for hCT grown in a membrane environment show primarily 
-sheet structures. Spectra taken from same samples as shown in Figure 3.2. All measurements and incubations were 
performed at 25 °C. Slight variations in mature -sheet signals are likely due to different polymorphs and degrees of 
membrane association.(1) 
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Figure B.6. ThT signal loss for 10 M hCT fibers is significantly greater than that seen in solution. LUV curves are 
the same as those shown in Figure 3.1. with the solution curve having been taken from the same plate. While 10 M 
hCT fibrils grown in solution maintain a stable plateau, fibrils in the presence of LUVs experience significant intensity 
loss. DO lipids show a more significant intensity loss than PO lipids. Displayed curves represent normalized averages 
of three independent trials at 25 °C in 20 mM phosphate buffer and 100 mM NaCl, pH 7.4. 
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Figure B.7. Higher temperatures induce fibril remodeling in all LUV compositions and peptide to lipid ratios. hCT at 
10 and 40 M was allowed to aggregate in the presence of 100 M of 100 nm LUVs composed of DOPC, POPC, 
and DMPC lipids at 35 °C. While both 10 M and 40 M hCT fibrils in solution show no appreciable signal loss, all 
LUV conditions show rapid and significant decline in ThT signal regardless of composition or peptide to lipid ratio. 
The uniform signal loss at higher temperatures suggests that such temperatures could overcome LUV-dependent 
energy barriers to fibril remodeling responsible for the different remodeling behaviors of PO and DO lipids.  Displayed 
curves represent normalized averages of three independent trials in 20 mM phosphate buffer and 100 mM NaCl, pH 
7.4. 
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